A4D-Ab

Aggrescan4D Antibody Database

Structurally guided assessment of aggregation propensity in clinical antibodies

Advanced Search & Filters

Antibody Registry (Level 1)

Antibody ID Antibody Name Target Name Primary Therapeutic Area Clinical Status Isotype Company Structures Max Seq. Identity Average A4D Score
A4DAB001 Abazistobart PDCD1/CD279/PD1 — TBC G4 Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd 1 100% -0.6954 1767 ['507427408'] 609A
A4DAB002 Abciximab ITGA2B/CD41 Cardiovascular / hemostasis disorders Approved G1 Janssen Biologics BV 1 100% -0.7092 146 ['7978624', '46505910', '49982017', '103771408', '135274203', '178103197', '329976973', '385780763', '440790666', '471144018', '471145855', '472219801', '472423469', '480410489', '481101467', '486453249', '498152712', '519834779'] c7E3;CentoRx;Centrex;ReoPro
A4DAB003 Abelacimab F11 Cardiovascular / hemostasis disorders Phase-III G1 Novartis 1 100% -0.6113 844 ['381128283', '442064645', '472419757', '476262747', '476269359', '479821208', '505547120', '505923885'] MAA-868
A4DAB004 Acimtamig FCGR3A/CD16/CD16A;TNFRSF8/CD30 — Phase-II non-canonical Affimed Therapeutics 2 95-98% -0.6236 1388 ['478838285', '494431237', '505057008'] AFM13;AFM-13
A4DAB005 Adalimumab TNF/TNFA Immune-mediated / inflammatory disorders Approved G1 Abbvie 10 100% -0.6736 165 ['46504982', '50070208', '103771314', '135335742', '178101561', '329976965', '354355035', '384647094', '385327551', '387061214', '440790468', '441072525', '459337310', '468796981', '469691022', '472217541', '472397579', '475546932', '481101469', '481155364', '489762953', '496156055', '496203373', '498214207', '505232365', '508644790', '513260571', '519878281', '520663123'] D2E7;HUMIRA
A4DAB006 Adintrevimab SARS-CoV-2 Spike Infectious diseases Phase-II/III G1 Adagio Therapeutics 2 99% -0.6308 1219 ['443566421', '461565701', '472423467', '476262754', '476269366', '513906932'] ADG-20;ADG20
A4DAB007 Aducanumab APP Neurological disorders Approved G1 Biogen 2 100% -0.7206 479 ['174505063', '252166537', '347911309', '381127201', '459143277', '464013616', '468569299', '472408372', '481155595', '483928245', '500131943', '518314162'] ADUHELM;BIIB 037;BIIB-037;NI-10;NI10
A4DAB008 Afasevikumab IL17A — Phase-I G1 NovImmune 2 100% -0.6878 576 ['160671724', '381127661', '404772248', '472408711', '476262755', '476269367'] MCAF-5352A;MCAF5352A;NI-1401;NI1401;RG-7624;RG7624;RO5553110
A4DAB009 Alemtuzumab CD52 Cancer Approved G1 Bayer HealthCare Pharmaceuticals Inc. 2 100% -0.7715 11 ['7978474', '46507379', '50070197', '103771414', '135330159', '178103376', '329976974', '384494226', '440790671', '464013610', '468568987', '472398050', '481101485', '481155365', '496156079', '498146340', '505184773', '519839756'] Campath;Campath-1H;LDP-03;LDP03;Lemtrada;Remniq
A4DAB010 Alomfilimab ICOS/CD278 — Phase-II G1 Kymab 1 100% -0.7145 1120 ['440235330', '442064702', '472419556'] KY-1044;KY1044;SAR-445256
A4DAB011 Amatuximab MSLN — Phase-II G1 Eisai Co Ltd 7 100% -0.6909 64 ['135289484', '160704149', '223366083', '347911395', '464013575', '468575015', '472392929', '481155558', '498124135', '505552597', '517704471'] MORAb-009; MORAB-009-006;MORAb009
A4DAB012 Amivantamab EGFR/ERBB1/HER1;MET/HGFR Cancer Approved G1;G1 Genmab 1 100% -0.7063 937 ['387065587', '402425829', '404719883', '472419032', '476262939', '476269205', '483927838', '498146128', '508533721'] CNTO4424;JNJ 372;JNJ372;JNJ-372;JNJ-61186372;JNJ61176372;JNJ-6372;JNJ6372;RYBREVANT
A4DAB013 Amlenetug SNCA/PARK1/PARK4 Neurological disorders Phase-III G1 Lundbeck 1 100% -0.7803 1539 ['440234775', '472420424'] LU AF82422
A4DAB014 Amubarvimab SARS-CoV-2 Spike RBD — Phase-II/III G1 Brii Biosciences 7 100% -0.6889 1215 ['442064652', '443565558', '472423204', '476262764', '476269425', '513906938'] BRII-196;BRII196
A4DAB015 Amulirafusp MS4A1/CD20 — Phase-I/II G1 ImmuneOnco Biopharmaceuticals 9 99% -0.6555 None IMM-0306;IMM 0306;IMM0306
A4DAB016 Anbenitamab ERBB2/CD340/HER2 (Domain II);ERBB2/CD340/HER2 (Domain IV) Cancer Phase-II/III G1;G1 Alphamab 73 100% -0.6925 1122 ['440234906', '440235066', '472419998', '476262766', '476269427'] KN-026;KN026
A4DAB017 Andecaliximab MMP9/GELB Skeletal disorders Phase-III G4 Gilead Sciences 3 100% -0.6696 533 ['329968449', '336908661', '381127584', '472407955', '476262685', '476269288', '496735072', '500718489'] GS-5745;GS5745
A4DAB018 Anifrolumab IFNAR1 Immune-mediated / inflammatory disorders Approved G1 Medarex 1 100% -0.7188 474 ['164144448', '249565938', '347911264', '381126987', '472220765', '472423585', '472435507', '472439886', '481155515', '483928463', '498153723', '508534504'] MDX-1333;MDX1333;MEDI-546;MEDI546;Saphnelo
A4DAB019 Anivovetmab Minor Capsid VP2 (Canine) — Unknown G2 Kindred Biosciences 2 95-98% -0.432 1237 ['461454353', '472424357', '476000909', '476262767', '476269428'] KIND030;KIND 030;KIND-030
A4DAB020 Ansuvimab Zaire Ebolavirus Glycoprotein Infectious diseases Approved G1 Ridgeback Biotherapeutics 2 99% -0.7004 1114 ['433770931', '440234910', '472421480', '483928999', '505057014', '513906939'] EVB114;EVB-114
A4DAB021 Anvatabart ERBB2/CD340/HER2 — Phase-II/III G1 Fudan University 60 100% -0.6964 None ARX788;ARX-788;ARX 788
A4DAB022 Anzurstobart SIRPA — Phase-I G1 Celgene Corporation 2 100% -0.6766 1362 ['462764898', '472420553', '476000790', '485483278', '485511860'] BMS-986351;BMS986351;CC-95251;CC95251
A4DAB023 Apitegromab pro-MSTN/GDF8/GDF-8/pro-GDF8 Muscular disorders Preregistration G4 Scholar Rock 2 95-98% -0.6681 829 ['404914099', '434122240', '440234904', '472422584', '476262770', '476269431'] SRK-015;SRK015
A4DAB024 Arcitumomab CEA/CEACAM — Approved (w) G1 Immunomedics 1 100% -0.6774 113 ['50070172', '135345795', '160671599', '472220672', '472399331', '480407832', '505555643']
A4DAB025 Arumakimig IL18;IL1B — TBC G1;G1 TBC 7 99% -0.7451 1781 ['482553799'] TBC
A4DAB026 Atezolizumab PDL1/CD274 Cancer Approved G1 Amgen 6 100% -0.6556 526 ['249565671', '318464470', '347911207', '354355059', '377483935', '384647093', '385327550', '387061104', '469690927', '472220847', '472423410', '475546938', '481101521', '485726055', '488217755', '491641505', '495673895', '496156057', '496291337', '498153264', '503452923', '505184775', '507699754', '508534491', '519870661'] MPDL-3280A;MPDL3280A;RG-7446;RG7446;RG7446-42;RO-5541267;RO5541267;TECENTRIQ
A4DAB027 Atisnolerbart Bet v 1 — Phase-III G4 Regeneron 2 100% -0.6742 1335 ['471299097', '474492731', '485483316', '485511889', '494431122'] REGN5713-5714-5715 (combination of Atisnolerbart; Bremzalerbart; and Umesolerbart)
A4DAB028 Atoltivimab Zaire Ebolavirus Glycoprotein — Phase-I G1 Regeneron Pharmaceuticals 2 100% -0.5636 927 ['381609025', '404720559', '472407746', '505057018', '505556050', '508534649', '513906962'] REGN 3470;REGN3470;REGN-3470;INMAZEB (combination with Maftivimab and Odesivimab)
A4DAB029 Avelumab PDL1/CD274 Cancer Approved G1 AIO Studien gGmbH 2 100% -0.586 512 ['252827393', '336908606', '347911260', '355203045', '355203157', '381127599', '472264634', '472423499', '481101526', '496735331', '498152138', '508534488', '519932891'] BAVENCIO;MSB-0010718C;MSB0010718;CPF-06834635;CPF06834635
A4DAB030 Azerutamig KLRK1/NKG2D/CD314;ERBB2/CD340/HER2 — Phase-II G1;G1 Dragonfly Therapeutics 50 99% -0.6974 1655 ['474492314', '520377978'] DF-1001;DF 1001;DF1001
A4DAB031 Bafisontamab EGFR/ERBB1/HER1;MET/HGFR — Phase-I/II G1;non-canonical EpimAb Biotherapeutics 4 100% -0.6884 1207 ['440234656', '443566315', '472420422', '476262784', '476269446'] EMB-01;EMB01
A4DAB032 Bamlanivimab SARS-CoV-2 Spike — Approved G1 Abcellera 3 100% -0.6193 1104 ['434321760', '434370493', '442064635', '472422427', '481155474', '483929052', '505057019'] LY 3819253;LY3819253;LY-3819253;LY CoV 555;LY-CoV-555
A4DAB033 Bapineuzumab APP Neurological disorders Phase-II G1 JANSSEN Alzheimer Immunotherapy 2 95-98% -0.7132 252 ['135311552', '160703828', '178103512', '347911230', '472399323', '472435518', '472440364', '481155507', '505556656', '519878786'] AAB-001;AAB001
A4DAB034 Barecetamab ERBB3/HER3 — Phase-I G1 ISU Abxis 2 100% -0.6866 1067 ['433770646', '442064854', '472422471', '476262791', '476269455'] ISU-104; ISU104
A4DAB035 Basiliximab IL2RA/CD25 Immune-mediated / inflammatory disorders Approved G1 Cerimon Pharmaceuticals 4 100% -0.6438 148 ['46505169', '50067184', '103771251', '135321271', '178103461', '440790690', '472386308', '472437799', '472440172', '481101529', '498150491', '519819562'] CHI 621;CHI621;CHI-621;Simulect
A4DAB036 Bebtelovimab SARS-CoV-2 Spike RBD — Approved G1 Eli Lilly 2 100% -0.6751 1238 ['442108338', '461565936', '461663476', '472424854', '483558686', '483559435', '483929079', '513906971'] LY-3853113;LY3853113;LY-CoV1404;LY CoV1404
A4DAB037 Belimumab TNFSF13B/CD257/BAFF Immune-mediated / inflammatory disorders Approved G1 Assistance Publique Hopitaux de Paris 8 100% -0.7071 266 ['131283241', '135353783', '178103469', '329976975', '347910378', '354355056', '441071577', '464013611', '468568983', '468808490', '472219954', '472422612', '480409562', '481101535', '486489711', '498138060', '519990320'] GSK1550188;GSK-1550188;HGS-1006;HGS1006
A4DAB038 Beludavimab SARS-CoV-2 Spike RBD — Phase-II G1 GlaxoSmithKline 56 99% -0.6843 1213 ['461435089', '461566053', '472424872', '476262797', '476269465', '513906972'] GSK-4182137;GSK4182137;VIR-7832;VIR7832
A4DAB039 Bemarituzumab FGFR2/CD332 Cancer Phase-III G1 Five Prime Therapeutics 4 95-98% -0.603 770 ['381128185', '434321713', '461566098', '464013579', '468575019', '472406659', '481155567', '505556954'] AMG-552;AMG552;FPA-144;FPA144
A4DAB040 Bentracimab AR-C124910XX Cardiovascular / hemostasis disorders Phase-III G1 MedImmune 2 100% -0.6296 516 ['404914104', '440234812', '472420255', '476262799', '476269467', '505557009', '507750309', '521253748'] MEDI-2452;MEDI2452;PB-2452;PB2452
A4DAB041 Benufutamab TNFRSF10B/CD262/DR5/TRAILR2 — Phase-I/II G1 Genmab 2 100% -0.7416 945 ['402425701', '472420478', '476262800', '476269468'] GEN1029;GEN-1029;Hx-DR5-01;Hx-DR5-05;iDD 004;iDD-004;iDD004
A4DAB042 Berlimatoxumab Staphylococcus aureus Toxin A — Phase-II G1 Adimab 2 100% -0.6749 764 ['381128180', '472421052', '476262802', '476269470'] ASN-2;ASN2;ASN200 (combination of atidortoxumab and berlimatoxumab);ASN-200
A4DAB043 Betinukibart IL17A Immune-mediated / inflammatory disorders Phase-III G1 Shanghai Huaota Biopharmaceutical 2 100% -0.6401 1704 ['507427492', '520376942'] Hb0017;Hb-0017
A4DAB044 Bevacizumab VEGFA Cancer Approved G1 All Ireland Cooperative Oncology Research Group 8 100% -0.6784 24 ['46504473', '50067187', '103771315', '135329020', '178103377', '329976976', '348480209', '350080043', '387061165', '440790697', '441072526', '445537291', '468769596', '469690934', '472217546', '472423468', '475546928', '481101539', '481152874', '485726125', '488297021', '496156058', '508644795', '513259655', '519821651'] 12-IgG1;rhuMAb-VEGF;AVASTIN
A4DAB045 Bexatamig IL3RA/CD123;NCR1/NKP46/NKp46/LY94/CD335 — Phase-I/II G1;G1 Innate Pharma 4 100% -0.7355 1546 ['496141639', '520377151'] NKp46-1;IPH-6101;IPH 6101;IPH6101;SAR-443579;SAR 443579;SAR443579;SAR’579
A4DAB046 Bezlotoxumab Clostridium difficile Toxin A Infectious diseases Approved G1 Medarex 2 100% -0.7328 411 ['160671640', '347911429', '377483929', '472213863', '472405119', '480403086', '481101543', '481985734', '496703304'] CDB1;CDB-1;MBL-CDB1;MBLCDB1;MDX 1388;MDX1388;MDX-1388;MK 6072;MK6072;MK-6072;Zinplava
A4DAB047 Bimagrumab ACVR2B — Phase-II G1 MorphoSys 6 100% -0.5185 456 ['194189084', '249565766', '347911347', '381127086', '472406523', '476262689', '476269292', '498153410', '505564077', '517689166'] BYM-338;BYM338
A4DAB048 Bimekizumab IL17A Immune-mediated / inflammatory disorders Approved G1 UCB 2 100% -0.754 486 ['328083513', '347911408', '381127331', '404719817', '472405709', '474488722', '474489058', '475546941', '498152918', '505564081'] Bimzelx;CDP-4940;CDP4940;UCB-4940;UCB4940
A4DAB049 Bintrafusp PDL1/CD274 — Approved G1 AIO Studien gGmbH 2 100% -0.586 None GSK-4045154;GSK4045154;M-7824;M7824;MSB-0011359C;MSB0011359C
A4DAB050 Bleselumab TNFRSF5/CD40 — Phase-II G4 Kirin Brewery 2 100% -0.6452 563 ['374364072', '381127499', '404772686', '472408007', '474488703', '474489038', '505565379'] ASKP 1240;ASKP1240;ASKP-1240
A4DAB051 Blontuvetmab MS4A1/CD20 — Unknown G2 Aratana Pharmaceuticals 2 95-98% -0.6902 593 ['312467840', '381127698', '472423038', '476262813', '476269481'] AT-004;AT004;VT-007;VT007
A4DAB052 Bococizumab PCSK9 Cardiovascular / hemostasis disorders Phase-III G2 Halozyme Therapeutics 1 100% -0.6573 485 ['194168554', '223366063', '347911335', '381127283', '472404650', '472435520', '472440368', '481155505', '505565523'] PF-04950615;PF04950615;PF-4950615;PF4950615;RN-316;RN316
A4DAB053 Boserolimab TNFRSF7/CD27 — Phase-II G1 Bionovion 1 100% -0.6878 1308 ['471299212', '472419510', '476000903', '485483263', '485511845'] MK-5890;MK5890
A4DAB054 Bremzalerbart Bet v 1 — Phase-III G4 Regeneron Pharmaceutical 2 100% -0.6361 1334 ['471298997', '474492837', '485483315', '485511888', '494431191'] REGN5713-5714-5715 (combination of Atisnolerbart; Bremzalerbart; and Umesolerbart)
A4DAB055 Briakinumab IL12B/CLMFp40 Immune-mediated / inflammatory disorders Preregistration (w) G1 Cambridge Antibody Technology 12 100% -0.6908 162 ['135292757', '160687953', '315661289', '347910151', '472220729', '472398910', '476262816', '476269484', '488233834', '498138517', '505565957'] A-796874.0;ABT-874;ABT874;BSF 415977;BSF-415977;BSF415977;J 695;J695;J-695;LU 415977;LU-415977;LU415977;Ozespa;WAY-165772;WAY165772
A4DAB056 Burosumab FGF23 Skeletal disorders Approved G1 Kyowa Hakko Kirin 1 100% -0.6481 647 ['318164811', '318464563', '381127714', '404771481', '472264636', '472408595', '476262723', '476269041', '481155334', '483928646', '498151791'] Crysvita;KRN 23;KRN23;KRN-23;UX 023;UX023;UX-023
A4DAB057 Canakinumab IL1B Immune-mediated / inflammatory disorders Approved G1 Charite - Universitatsmedizin Berlin 7 99% -0.7451 244 ['103771532', '135332926', '178103379', '329976978', '347910340', '381124992', '381124993', '440790483', '472211472', '472422543', '472437798', '472440170', '481101555', '481155460', '498124530', '519933425'] ACZ-885;ACZ885;Ilaris
A4DAB061 Caplacizumab VWF Cardiovascular / hemostasis disorders Approved non-canonical Ablynx 4 100% -0.6045 401 ['160671749', '315661208', '381125787', '404770101', '472423118', '472435550', '472440357', '481155461', '483929155', '498124476', '517689394', '517704479'] ALX-0081;ALX0081;ALX-0681;ALX0681
A4DAB058 Carlumab CCL2/MCP1 — Phase-II G1 MorphoSys 2 99% -0.6651 359 ['135350336', '160698790', '347911366', '472397238', '472435521', '472440369', '481155504', '498124491', '505570407'] CNTO-888;CNTO888
A4DAB059 Casdozokitug IL27 — Phase-II G1 Surface Oncology 2 100% -0.7054 1337 ['471299240', '474492350', '485483269', '485511851', '494431227'] SRF 388;SRF-388;SRF388
A4DAB060 Caxmotabart ERBB2/CD340/HER2 — Phase-III G1 LegoChem Biosciences 60 100% -0.6964 1701 ['507433214', '520377986'] FS-1502;FS 1502;FS1502;IKS-014;IKS 014;IKS014;LCB-14;LCB 14;LCB14;LCB14-0110
A4DAB061 Cemiplimab PDCD1/CD279/PD1 Cancer Approved G4 Inovio Pharmaceuticals 4 100% -0.6045 846 ['381118800', '381128019', '404720555', '404772158', '472264637', '472422351', '472435530', '472440390', '481155488', '483928738', '498150355', '508534640'] Libtayo;REGN-2810;REGN2810;SAR-439684;SAR439684
A4DAB062 Certolizumab TNF/TNFA — Approved G1 UCB 4 100% -0.6437 None ['135347437', '404719925', '472399115', '481155459', '505570956'] CDP-870;CDP870;Cimzia;PHA-738144;PHA738144;Simziya
A4DAB063 Cetuximab EGFR/ERBB1/HER1 Cancer Approved G1 Array BioPharma 70 100% -0.6741 151 ['495888', '532611', '46507042', '103771411', '135293496', '178103464', '329976961', '348480208', '348892040', '350080042', '354355046', '387061106', '440790714', '441072527', '445933985', '446094829', '468762434', '469690936', '472186809', '472386399', '472677711', '475546936', '481101564', '481155116', '485441611', '488235390', '496156059', '497705298', '498148318', '500132709', '507648546', '508644796', '513261102', '519964949'] IMC-C225;IMC C225;LY-2939777;LY2939777
A4DAB064 Cilgavimab SARS-CoV-2 Spike RBD — Approved G1 AstraZeneca 7 100% -0.7102 1106 ['434321764', '434370388', '442064696', '472423048', '476262905', '476269523', '483928820', '513907002'] AZD1061;AZD-1061;COV2-2130;AZD7442 (combination of cilgavimab and tixagevimab);AZD-7442 (combination of cilgavimab and tixagevimab);EVUSHELD (combination of cilgavimab and tixagevimab)
A4DAB065 Cinpanemab SNCA/PARK1/PARK4 — Phase-II G1 Neurimmune Therapeutics 2 100% -0.7188 930 ['336908608', '381128265', '472419912', '476262690', '476269293', '496703301'] BIIB 054;BIIB-054;BIIB054
A4DAB066 Cinrebafusp ERBB2/CD340/HER2 — Phase-II G4 Eli Lilly and Company 60 100% -0.6964 None PRS-343;PRS343
A4DAB067 Clesrovimab RSV gpF Infectious diseases Preregistration G1 Merck Sharp & Dohme 8 100% -0.7571 1245 ['404719966', '442030466', '472421161', '476262942', '476269598', '513907005'] MK-1654;MK1654;RB1;RB-1
A4DAB068 Cobolimab HAVCR2/TIM3 Cancer Phase-III G4 AnaptysBio 1 100% -0.708 886 ['381128219', '404719772', '472419575', '480403231', '481988094', '505573975', '513904321', '517704467'] GSK-4069889;GSK4069889;TSR 022;TSR-022;TSR022;WBP 296A;WBP-296A;WBP296A
A4DAB069 Coltuximab CD19 — Phase-II G1 ImmunoGen 2 100% -0.6826 None SAR3419;SAR-3419
A4DAB070 Conatumumab TNFRSF10B/CD262/DR5/TRAILR2 — Phase-II G1 Amgen 3 100% -0.7386 224 ['135311444', '160677288', '347911222', '349975224', '472220497', '472386192', '474488706', '474489041', '498125034', '505574321'] AMG-655;AMG655
A4DAB071 Concizumab TFPI Cardiovascular / hemostasis disorders Approved G4 Novo Nordisk 1 100% -0.7296 447 ['347911387', '381126946', '404719421', '434122242', '472404613', '476262664', '476269271', '498153827', '505574327'] mAb-2021;mAb2021;NN-7415;NN7415
A4DAB072 Coprelotamab ERBB2/CD340/HER2 Cancer Phase-III G1 Genor Biopharma 60 100% -0.6964 1076 ['433770704', '472422507', '485482287', '485511927'] GB 221;GB221;GB-221
A4DAB073 Cosfroviximab Zaire Ebolavirus Glycoprotein — Phase-II G1 Mapp Biopharmaceutical 10 99% -0.6165 726 ['374364131', '381127999', '472408735', '480403232', '481988095'] c13C6-FR1-N
A4DAB074 Crenezumab APP — Phase-II G4 AC Immune 3 100% -0.7317 378 ['160693412', '178103516', '347911262', '381126310', '472397307', '480403235', '481988098', '505575133', '513904335', '519918852'] MABT5102A;MABT-5102A;R 5490245;R5490245;R-5490245;RG 7412;RG7412;RG-7412;RO 5490245;RO5490245;RO-5490245
A4DAB075 Crexavibart SARS-CoV-2 Spike RBD — Phase-II/III G1 NIAID 3 99% -0.5147 1247 ['472426073', '476000912', '485482221', '485510055', '513907015'] C-144-LS;BMS-986413;BMS986413;BMS 986413
A4DAB076 Crovalimab C5 Cardiovascular / hemostasis disorders Approved G1 Chugai Pharmaceutical 2 100% -0.6993 783 ['381128162', '440234576', '472418753', '480403257', '481988122', '483123338', '505575202', '508534419'] CH 7092230;CH7092230;CH-7092230;RG 6107;RG-6107;RG6107;RO 7092230;RO-7112689;RO7112689;SKY 59;SKY-59;SKY59
A4DAB077 Cugrastomig LAG3/CD223;PDCD1/CD279/PD1 — Phase-I/II G1;non-canonical Akeso Biopharma 2 95-98% -0.6896 1554 ['496143715', '520378124'] AK 129;AK-129;AK129
A4DAB078 Dacetuzumab TNFRSF5/CD40 — Phase-II G1 Seattle Genetics 4 100% -0.7165 232 ['135323347', '160666624', '347911348', '349991504', '464013582', '468575037', '472220376', '472398106', '481155346', '498125441', '505580875'] huS2C6;PRO 64553;PRO-64553;PRO64553;RG 3636;RG3636;RG-3636;SGN 14;SGN14;SGN-14;SGN-40;SGN40
A4DAB079 Daclizumab IL2RA/CD25 — Approved G1 AbbVie 3 100% -0.725 36 ['538071', '46504469', '50067188', '103771419', '135342174', '178103462', '329976980', '464011639', '468568979', '472264639', '472399229', '481101586', '481155335', '486455968', '517704477'] BIIB-019;BIIB019;Dacliximab;RO 247375;RO247375;RO-247375;Zenapax;Zinbryta
A4DAB080 Danvilostomig CTLA4/CD152;PDCD1/CD279/PD1 — Phase-II G1;non-canonical Sichuan Baili Pharmaceutical 13 100% -0.6732 1322 ['471298962', '474494426', '494430972'] SI-B003;SI B003
A4DAB081 Daratumumab ADPRC1/CD38 Cancer Approved G1 Boston Medical Center 3 100% -0.6838 301 ['135304352', '160671954', '178103967', '347910441', '354355058', '387060189', '440806798', '461629168', '463561439', '469691026', '472264640', '472398913', '475546927', '481101587', '481155332', '488237781', '498123744', '500131955', '513259907'] DALINVI;Darasarex;DARZALEX;HuMax-CD38;JNJ-54767414;JNJ54767414
A4DAB082 Demupitamab EGFR/ERBB1/HER1 — Phase-I G1 Sinocelltech 4 99% -0.6884 1007 ['405023536', '472421862'] N63Ab
A4DAB083 Denecimig F9;F10 Cardiovascular / hemostasis disorders Phase-III G4;G4 Genmab 3 100% -0.7305 1314 ['471299237', '474492340', '485483309', '485511883', '494431296'] NN-7769;NN7769;NNC0365-3769;Mim8;Mim-8
A4DAB084 Denrakibart CCL17/ABCD-2/SCYA17/TARC — Phase-II G2 GSK 5 99% -0.6884 1670 ['507428640', '520377656'] GSK-3858279;GSK 3858279 ;GSK3858279
A4DAB085 Dilpacimab DLL4;VEGFA — Phase-II G1;G1 AbbVie 8 100% -0.6784 847 ['381127994', '440234804', '472419734', '480403240', '481988103', '513904495'] ABT-165;ABT165
A4DAB086 Dinutuximab Ganglioside GD2 Cancer Approved G1 National Cancer Institute (USA) 7 95-98% -0.6777 464 ['194168552', '249565662', '347910402', '377483933', '472264642', '472406980', '481101594', '481155367', '483764322', '483765023'] ch14.18;Ch14.18OP 08;OP08;OP-08
A4DAB087 Diridavumab Influenza A HA2 — Phase-II G1 National Institute of Allergy and Infectious Diseases 25 100% -0.5563 494 ['194161622', '347911350', '381127237', '472407523', '480403241', '481988104', '513907039'] CR-6261;CR6261;JNJ-54235025;JNJ54235025;mAb CR6261;mAb-CR6261
A4DAB088 Domagrozumab MSTN/GDF8/GDF-8 — Phase-II G1 Kennedy Krieger Institute 4 99% -0.6355 610 ['312467841', '315661181', '381127799', '404772525', '472406804', '480403243', '481988106', '505586090'] PF 6252616;PF6252616;PF-06252616;PF06252616
A4DAB089 Donzakimig1 IL22;ALB — Phase-I/II G1;non-canonical UCB Biopharma 2 99% -0.6867 1473 ['485663823', '494431019'] UCB-1381;UCB 1381;UCB1381
A4DAB090 Dostarlimab PDCD1/CD279/PD1 Cancer Approved G4 AnaptysBio 1 100% -0.6285 849 ['381128218', '404720301', '441604890', '472407780', '476262679', '476269281', '483928936', '498148676', '500131949', '505188562'] ANB 011;ANB011;ANB-011;GSK-4057190;GSK4057190;JEMPERLI;TSR 042;TSR042;TSR-042;WBP 285;WBP285;WBP-285
A4DAB091 Drozitumab TNFRSF10B/CD262/DR5/TRAILR2 — Phase-II G1 Genentech 1 100% -0.7408 348 ['135329142', '160693414', '472398111', '474488724', '474489060', '513904547'] PRO-95780;PRO95780;RG7425;RG-7425
A4DAB092 Duligotuzumab ERBB3/HER3 — Phase-II G1 Genentech 4 95-98% -0.6912 416 ['194168553', '347911288', '381126959', '472423075', '485482297', '485511937', '505586193'] MEHD-7945A;MEGD7945A;RG 7597;RG7597;RG-7597;RO-5541078;RO5541078
A4DAB093 Dupilumab IL4R/CD124 Immune-mediated / inflammatory disorders Approved G4 Aimmune Therapeutics 11 100% -0.6944 449 ['160682326', '223365910', '347911292', '377014283', '402355847', '402356185', '472264643', '472404580', '481101603', '481155368', '496203374', '498154910', '513260021', '517704480'] Dupixent;REGN-668;REGN668;SAR-231893;SAR231893
A4DAB094 Durvalumab PDL1/CD274 Cancer Approved G1 Advaxis 2 100% -0.7129 528 ['242651787', '249565666', '347911229', '381127393', '384647100', '385327558', '472220163', '472406347', '481101604', '481155339', '498152811', '505194536', '508534492', '519940455'] Imfinzi;MEDI-4736;MEDI4736
A4DAB095 Eblasakimab IL13RA1/CD213A1 — Phase-II G4 ASLAN Pharmaceuticals 2 95-98% -0.6957 1210 ['443565724', '458923805', '472422539', '485482300', '485511940'] ASLAN 004;ASLAN-004;ASLAN004;CSL 334;CSL334;CSL-334;MK 6105;MK6105;MK-6105
A4DAB096 Ebribafusp C3d — Phase-II G4 Q32 Bio 1 100% -0.6495 None 3d8b;ADX-097;ADX 097;ADX097
A4DAB097 Eculizumab C5 Immune-mediated / inflammatory disorders Approved G2 Alexion Pharmaceuticals 2 100% -0.7165 37 ['46505429', '50070199', '103771526', '135288438', '178103466', '329976982', '354355052', '387060186', '440790757', '464013606', '468568938', '469691029', '472264644', '472422565', '481101607', '481155333', '485726231', '488204050', '496156062', '498145775', '508644802'] 5G1-1;5G1.1;Soliris
A4DAB098 Efalizumab ITGAL/CD11A/LFA1A — Approved G1 Genentech 5 100% -0.7356 38 ['46505252', '50069676', '103771313', '135272703', '178103206', '329976983', '472399419', '472439124', '472441179', '480406065', '481101608', '488204503', '498146495'] HU 1124;HU1124;HU-1124;Raptiva;Xanelim
A4DAB099 Elgemtumab ERBB3/HER3 — Phase-I/II G1 MorphoSys 1 95-98% -0.6673 534 ['252827373', '381127578', '404719829', '404772857', '472405967', '480403249', '481988112'] LJM-716;LIM716;NOV-6;NOV6
A4DAB100 Elipovimab HIV-1 gp120 — Phase-I G1 Gilead Sciences 6 95-98% -0.6406 909 ['381608803', '472213841', '472418775', '480403250', '481988113', '513907056'] GS-9722;GS9722
A4DAB101 Eltrekibart CXCL1/CXCL2/CXCL3/CXCL5/CXCL6/CXCL7/CXCL8 — Phase-II G4 Eli Lilly 8 100% -0.6963 1476 ['478837149', '494431195'] LY 3041658;LY-3041658;LY3041658
A4DAB102 Emactuzumab CSF1R/CD115/M-CSFR Cancer Phase-III G1 Roche 1 100% -0.6996 501 ['310264725', '312468220', '381127464', '404772350', '472408545', '472435564', '472439870', '498152583', '505586462'] RG-7155;RG7155;RO-5509554;RO5509554
A4DAB103 Empasiprubart C2 Immune-mediated / inflammatory disorders Phase-III G1 arGEN-X 2 100% -0.7491 1341 ['471298999', '474493504', '485483270', '485511852', '494431087'] ARGX-117;ARGX117
A4DAB104 Enlonstobart PDCD1/CD279/PD1 Cancer Approved G4 Hangzhou Sumgen Biotech 4 95-98% -0.7558 1397 ['478838800', '485483330', '485511897', '494431275', '507750422'] SG 001;SG-001;SG001;SYSA-1802;SYSA 1802;SYSA1802
A4DAB105 Enuzovimab SARS-CoV-2 Spike RBD — Phase-I G4 ABL Bio 1 100% -0.6312 1218 ['443565912', '472422476', '497622031', '497623151'] HFB-3013;HFB3013;HFB30132A;HFB-30132A;P4A1-2A
A4DAB106 Epcoritamab CD3E;MS4A1/CD20 Cancer Approved G1;G1 Genmab 3 95-98% -0.701 949 ['402425939', '440816811', '442064636', '472420475', '482320770', '482321847', '483928971', '513904629'] ABBV-GMAB-3013;EPKINLY;GEN-3013;GEN3013;ABBV3013;ABBV-3013;Tepkinly
A4DAB107 Epratuzumab SIGLEC2/CD22 Cancer Phase-III G1 Charite - Universitatsmedizin Berlin 6 99% -0.725 40 ['135308971', '160682287', '249565768', '347909859', '472220415', '472420636', '474488726', '474489072', '505586723', '519819851'] AMG 412;AMG412;AGM-412;Epratucyn;IMMU 103;IMMU103;IMMU-103;IMMU LL2;IMMU-LL2;LymphoCide
A4DAB108 Eramkafusp MS4A1/CD20 — Phase-I G1 Spectrum Pharmaceuticals 12 100% -0.6384 None IGN-002;IGN002
A4DAB109 Erenumab CALCRL Neurological disorders Approved G2 Amgen 6 100% -0.6912 618 ['315661325', '336908642', '381127645', '404771503', '464013609', '468569153', '472245749', '472407793', '481155576', '483928628'] Aimovig;AMG-334;AMG334
A4DAB115 Erfonrilimab PDL1/CD274;CTLA4/CD152 Cancer Phase-III G1 Alphamab 12 100% -0.6882 1127 ['440235329', '442064786', '472422165', '497622032', '497623152'] KN-046;KN046
A4DAB110 Erlizumab ITGB2/CD18 — Phase-II G1 Genentech 1 100% -0.796 280 ['50069679', '135335294', '160709192', '472423143', '497387791', '497391296', '513904640']
A4DAB111 Erzotabart ADPRC1/CD38 — Phase-I/II G1 Genmab 1 100% -0.6988 1399 ['472423120', '485483288', '485511864', '494430904'] GEN-3014;GEN3014;GEN 3014
A4DAB112 Etesevimab SARS-CoV-2 Spike RBD — Approved G1 Eli Lilly and Company 2 100% -0.6483 1107 ['434321766', '434370465', '442064771', '472422390', '476262681', '476269283', '481155452', '483929053'] JS 016;JS-016;JS016;JS16;JS-16;JS 16;LY 3832479;LY-3832479;LY3832479;LY-CoV-016
A4DAB113 Evunzekibart TNFRSF9/CD137/4-1BB — Phase-I G4 Alligator Bioscience 2 100% -0.5052 1336 ['471299315', '474494052', '476000994', '485483317', '485511890'] ATOR-1017;ATOR1017
A4DAB114 Falbikitug LIF — Phase-II G1 AstraZeneca 1 100% -0.7612 1401 ['478838295', '485483291', '485511866', '494431198'] AZD0171;AZD-0171;MSC-1;MSC1
A4DAB115 Faricimab VEGFA;ANGPT2 Ophthalmic disorders Approved G1;G1 Chugai Pharmaceutical 12 100% -0.6882 793 ['381127689', '404720615', '404772735', '440816789', '471144014', '471146760', '472419366', '483928640', '508534505'] RG 7716;RG7716;RG-7716;RO 6867461;RO6867461;RO-6867461;Vabysmo
A4DAB116 Fepixnebart EREG — Phase-II G4 Eli Lilly and Company 1 100% -0.6451 1360 ['440234900', '462764887', '472420502', '485483321', '485511894'] LY-3016859;LY 3016859;LY3016859
A4DAB117 Ficerafusp EGFR/ERBB1/HER1 — Phase-II/III G1 Bicara Therapeutics 70 100% -0.6741 None BCA101;BCA-101
A4DAB118 Fidasimtamab PDCD1/CD279/PD1;ERBB2/CD340/HER2 — Phase-I G1;G1 Hanmi Pharmaceutical 60 100% -0.6964 1171 ['443565555', '472424595', '476262918', '476269546', '498143060'] BH-2950;BH2950;IBI-315;IBI315
A4DAB119 Fontolizumab IFNG — Phase-II G1 PDL BioPharma 3 99% -0.7401 43 ['135326524', '160671620', '347909951', '363894141', '472397752', '474488729', '474489076', '505595323'] HuZAF
A4DAB120 Fresolimumab TGFB — Phase-I G4 Cambridge Antibody Technology 10 99% -0.6565 174 ['135281361', '160687956', '252166476', '347911330', '464013587', '468575045', '472220980', '472385904', '481155555', '505596123'] GC-1008;GC1008
A4DAB121 Fulranumab NGFB Neurological disorders Phase-III G2 Janssen Pharmaceuticals 1 99% -0.6875 363 ['135329083', '160677291', '310264744', '347911282', '472220005', '472423438', '472439118', '472441267', '481155491', '505603426'] AMG-403;AMG403;JNJ-42160443;JNJ42160443
A4DAB128 Gacovetug F4+ ETEC (Veterinary Application) — TBC A1 Vrije Universiteit Brussel 1 100% -0.7298 1706 ['507433200', '520377314'] TBC
A4DAB122 Galegenimab HTRA1 — Phase-II G1 Roche 8 100% -0.7578 1169 ['443566053', '458923794', '461565846', '472418806', '476262928', '476269556'] FHTR2163;FHTR-2163;RG-6147;RG6147;RO-7171009;RO7171009
A4DAB123 Galvokimig1 IL17A and IL17F;ALB — TBC G1;non-canonical TBC 4 100% -0.7204 1480 ['485665267', '494431063'] TBC
A4DAB124 Gantenerumab APP Neurological disorders Phase-III G1 MorphoSys 2 100% -0.6953 223 ['135308536', '160704154', '178103515', '347911273', '464013589', '468575048', '472386067', '481155594', '505635349'] R-1450;R1450;RG-1450;RG1450;RO-4909832;RO4909832
A4DAB125 Garadacimab F12 Cardiovascular / hemostasis disorders Approved G4 CSL Behring 2 100% -0.5753 915 ['381609316', '472421284', '476262930', '476269559', '496703372', '505635350'] CSL 312;CSL312;CSL-312
A4DAB126 Gatralimab CD52 — Phase-I G1 Sanofi 2 100% -0.7304 951 ['402425778', '472421562', '476262934', '476269563', '520376870'] GZ-402668;GZ402668
A4DAB127 Gedivumab Influenza A HA — Phase-II G1 Genentech 1 95-98% -0.5783 719 ['381128046', '404720133', '404772709', '472418277', '476262936', '476269565', '505635517', '513907082'] MHAA-4549A;MHAA4549A;RG 7745;RG7745;RG-7745;RO 6876802;RO6876802;RO-6876802
A4DAB135 Gefurulimab C5;ALB Immune-mediated / inflammatory disorders Phase-III non-canonical Alexion Pharmaceuticals 1 100% -0.7061 1253 ['445594975', '472425520', '476000782', '476262937', '476269566', '508534152'] ALXN-1720;ALXN1720
A4DAB128 Gemtuzumab SIGLEC3/CD33/p67 — Approved G4 UCB 1 100% -0.7298 44 ['53787868', '135302348', '160676944', '404336834', '464011644', '472406644', '480408021', '481983179', '486424846', '513904859', '519845698'] CDP-771;CDP771 CMA-676;CMA676;Mylotarg
A4DAB129 Gevokizumab IL1B — Phase-III G2 IRIS 2 100% -0.7168 102 ['135322326', '160704155', '178103966', '347911285', '472220670', '472390562', '472435509', '472439889', '481155512', '498155311', '505635645'] S-78989;S78989;S 78989;VPM 087;VPM087;VPM-087;VPM87;VPM-87;XMA-005.2;XMA-0052;XMA52;XOMA-052;XOMA052;XOMA52;XOMA-52
A4DAB130 Ginisortamab GREM1 — Phase-I/II G4 UCB 1 100% -0.7251 1167 ['442064868', '443566107', '458923804', '472422648', '476264150', '476270760', '498142835'] UCB6114;UCB-6114
A4DAB131 Glenzocimab GP6 Cardiovascular / hemostasis disorders Phase-II/III G1 Acticor Biotech 1 100% -0.7061 901 ['385157206', '442064642', '472422749', '476264151', '476270761', '513649704', '513904873'] ACT-017;ACT017;ACT17;ACT-17
A4DAB132 Glofitamab CD3E;MS4A1/CD20 Cancer Approved G1;G1 Roche 4 100% -0.6894 952 ['402425894', '404720264', '464013591', '468575052', '472419993', '481155467', '483123306', '483927794', '498145174', '505188564'] Columvi;RG 6026;RG6026;RG-6026;RO 7082859;RO-7082859;RO7082859
A4DAB141 Gocatamig1 CD3E;ALB — Phase-I/II non-canonical Harpoon Therapeutics 3 95-98% -0.724 1564 ['496141579', '520377940'] HPN328;HPN 328;HPN-328;MK-6070;MK6070 ;MK 6070
A4DAB133 Golimumab TNF/TNFA Immune-mediated / inflammatory disorders Approved G1 Centocor 6 100% -0.5842 175 ['103771531', '135329319', '178103382', '329976985', '347910358', '349071996', '354355047', '440791136', '471144009', '471145846', '472219882', '472386363', '481101645', '498135571', '513904903'] CNTO-148;CNTO148;CNTO 148;MK-8259;MK8259;MK 8259;SCH 900259;SCH900259;SCH-900259;Shinponi;Simponi;Symposony;Xinpini
A4DAB134 Golocdacimab OLR1/LOX1 — Phase-II G1 MedImmune 1 100% -0.6365 1254 ['461453415', '472419700', '476001044', '476264153', '476270763'] MEDI-6570;MEDI 6570;MEDI6570
A4DAB135 Gotistobart CTLA4/CD152 Cancer Phase-III G1 OncoImmune 1 100% -0.7061 1403 ['472422092', '485483294', '485511869', '494430994'] BNT-316;BNT316;BNT 316;ONC-392;ONC392;ONC 392
A4DAB136 Gremubamab PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas) — Phase-II G1;G1 MedImmune 4 95-98% -0.6689 953 ['377483940', '404719677', '404772458', '472421156', '476264156', '476270766', '496703344', '505778447'] MEDI-3902;MEDI3902;MEDI 3902
A4DAB137 Guselkumab IL23A Immune-mediated / inflammatory disorders Approved G1 Janssen Biotech 2 100% -0.6623 468 ['164136017', '249565678', '347911245', '381127047', '461629172', '468568978', '472264647', '472404808', '481101646', '481154871', '498153475', '517704481'] CNTO-1959;CNTO 1959;CNTO1959;TREMFYA
A4DAB138 Ibalizumab CD4 Infectious diseases Approved G4 Biogen Idec 3 100% -0.7457 241 ['3720768', '135347929', '160671956', '347911363', '381744890', '464013594', '468575068', '472213849', '472397460', '481155466', '483929330', '498129210'] Hu1A8;Hu5A8;TMB-355;TMB 355;TMC355;TNX-355;TNX 355;TNX355;Trogarzo
A4DAB139 Ibritumomab MS4A1/CD20 — Approved G1 Biogen 1 100% -0.6649 None ['46506112', '135305414', '319416193', '385637780', '405469868', '440016529', '446242497', '461827117', '471080662', '472220715', '485987002'] BAY86-5128;IDEC-129;IDEC 129;IDEC129;SH-L-749;Zevalin;Zevamab
A4DAB140 Idarucizumab Dabigatran Cardiovascular / hemostasis disorders Approved G1 Boehringer Ingelheim 3 100% -0.6076 462 ['252166510', '312467846', '347910427', '381127112', '469688591', '472264648', '472406919', '481101666'] BI-655075;BI655075;BI 655075;Praxbind;Prizbind
A4DAB141 Imalumab MIF — Phase-II G1 Cytokine PharmaSciences 3 100% -0.724 504 ['381127401', '404772983', '442064846', '472408246', '473142887', '473143906'] BAX-069;BAX069;BAX 069;BAX-69;BAX69;BAX 69
A4DAB142 Infliximab TNF/TNFA Immune-mediated / inflammatory disorders Approved G1 Centocor 13 100% -0.6929 156 ['46505602', '50067186', '91145133', '103771449', '135305802', '178101701', '329976987', '348825932', '354355050', '387060165', '433790701', '433791528', '440790341', '441072528', '468742313', '469690933', '472186725', '472423472', '475546921', '481101685', '481155370', '485726170', '486300343', '488211629', '496156064', '498150919', '508644815', '513259867', '519875136'] cA2; CenTNF;Remicade;TA-650;TA650;TA 650
A4DAB143 Invikafusp TRBV6&TRBV10 — Phase-II G1 Marengo Therapeutics 1 100% -0.7461 None STAR 0602;STAR0602;STAR-0602
A4DAB144 Ipilimumab CTLA4/CD152 Cancer Approved G1 Aduro BioTech 13 100% -0.6732 180 ['131273201', '135287563', '178103470', '329976988', '347910341', '349072362', '354355037', '384647090', '385327547', '387061107', '442104697', '472264650', '472422344', '472634117', '475546933', '481101721', '481155433', '488211787', '496156065', '498214777', '505185876', '508534487', '508644820', '513253722', '519883502'] BMS-734016;BMS734016;MDX-010;MDX010;MDX 010;MDX-10;MDX10;MDX 10;Yervoy
A4DAB145 Isatuximab ADPRC1/CD38 Cancer Approved G1 ImmunoGen 1 100% -0.6616 539 ['252827377', '312467981', '381127523', '404772261', '440801540', '461629177', '463589857', '472423060', '481155586', '483928573', '498152441'] hu38SB19;SAR-650984;SAR650984;Sarclisa
A4DAB155 Isecarosmab ADAMTSL5;ALB — Phase-I non-canonical Merck 1 95-98% -0.6027 1014 ['405023088', '472422143', '480403110', '481987965'] M-6495;M 6495;M6495
A4DAB146 Itanistomig PDL1/CD274;IAP/CD47 — TBC G1;non-canonical TBC 1 100% -0.6982 1656 ['507428571', '520377746'] TBC
A4DAB147 Ivonescimab VEGFA;PDCD1/CD279/PD1 Cancer Approved G1 Akeso Biopharma 8 100% -0.6784 1196 ['443565665', '472420269', '480403114', '481987969', '496703366', '518314160', '520377299'] AK-112;AK 112;AK112;SMT-112;SMT112;SMT 112
A4DAB148 Ixekizumab IL17A Immune-mediated / inflammatory disorders Approved G4 Eli Lilly 2 100% -0.6935 380 ['160704157', '187051842', '347911203', '377483925', '381126990', '461629170', '463561820', '472264651', '472409975', '481101723', '481155371', '498155235'] LY-2439821;LY2439821;LY 2439821;Taltz
A4DAB149 Izalontamab EGFR/ERBB1/HER1;ERBB3/HER3 Cancer Phase-III G1;non-canonical Systimmune 70 100% -0.6741 1260 ['461454359', '472423697', '476000853', '480403115', '481987970'] SI-1X6.4;SI1X6;SI 1X6;SI-B001;SI-1;SI 1;SI1;SI B001
A4DAB150 Lampalizumab CFD Ophthalmic disorders Phase-III G1 Tanox 4 100% -0.7005 421 ['160687723', '252166506', '347911244', '381126863', '472405406', '474488734', '474489085', '505794157', '513905188'] FCFD4514S;RG7417;RG-7417;RG 7417;RO 5490249;RO5490249;RO-5490249;TNX-234;TNX 234;TXN234
A4DAB151 Lanadelumab KLKB1 Cardiovascular / hemostasis disorders Approved G1 Dyax 4 100% -0.6578 607 ['312468039', '315661179', '381127378', '404772049', '471144008', '471146751', '472406758', '483928547'] DX-2930;DX2390;DX 2930;OHB-401;OHB401;OHB 401;SHP 643;SHP-643;SHP643;TAK-743;TAK743;TAK 743;Takhzyro
A4DAB152 Larcaviximab Zaire Ebolavirus Glycoprotein — Phase-II G1 Mapp Biopharmaceutical 3 99% -0.6227 728 ['374364093', '381127998', '472408642', '480403123', '481987979', '513907199'] c4G7-N
A4DAB153 Lebrikizumab IL13 Immune-mediated / inflammatory disorders Approved G4 Chugai Pharmaceutical 1 100% -0.7039 325 ['135312293', '160693416', '223366019', '347911256', '472397316', '481155563', '498123574', '505794595', '508533758'] DRM 06;DRM-06;DRM06;DRM 6;DRM-6;DRM6;LY 3650150;LY-3650150;LY3650150;MILR1444A;MILR-1444A;MILR 1444;ARG 3637;ARG-3637;ARG3637;RO 5490255;RO-5490255;RO5490255;TNX 650;TNX-650;TXN650
A4DAB154 Lexatumumab TNFRSF10B/CD262/DR5/TRAILR2 — Phase-I G1 Cambridge Antibody Technology 1 95-98% -0.7408 183 ['135349517', '160682607', '349353292', '404770338', '468892062', '472220702', '472399325', '474488735', '474489086', '480405382', '498126540', '505794780', '519927767'] HGS-ETR2
A4DAB155 Lirentelimab SIGLEC8/SAF2 Immune-mediated / inflammatory disorders Phase-III G1 Allakos 1 99% -0.6027 832 ['404719698', '434150868', '472418890', '476262705', '476269314'] AK 002;AK002;AK-002;AK2;AK-2;AK 2;Antolimab
A4DAB156 Lirilumab KIRD2 — Phase-II G4 Novo Nordisk 1 100% -0.5958 423 ['160693186', '318164829', '347911236', '381126010', '472405237', '472435534', '472440389', '481155331', '498156073'] BMS-986015;BMS986015;BMS 986015;IPH-21;IPH21;IPH 21;IPH-2101;IPH2101;IPH 2101;IPH-2102;IPH 2102;IPH2102;NN 1975;NN1975;NN-1975;ONO-4483;ONO4483;ONO 4483
A4DAB157 Loncastuximab CD19 — Approved G1 ADC Therapeutics 2 99% -0.6826 759 ['381128134', '404719612', '472419163', '480403138', '481987996', '498149819'] ADCT-402;ADCT402;ADCT 402;MT-2111;MT2111;MT 2111;ZYNLONTA
A4DAB158 Lorigerlimab PDCD1/CD279/PD1;CTLA4/CD152 — Phase-II G4;G4 MacroGenics 6 95-98% -0.6755 1189 ['443566461', '472419608', '476000871', '480403139', '481987997'] AEX1344;AEX-1344;AEX 1344;EXPASY;MGD-019;MGD019;MGD 019;MGD19;MGD-19;MGD 19
A4DAB159 Lorukafusp Ganglioside GD2 — Phase-II G1 Lexigen Pharmaceuticals 7 95-98% -0.6777 None APN 301;APN301;APN-301;ch14.18-IL2;EMD 273063;EMD-273063;EMD273063
A4DAB160 Lotivibart HIV-1 gp120 — TBC G1 TBC 1 95-98% -0.7034 1664 ['507427715', '520376809'] TBC
A4DAB161 Lumiliximab FCER2/CD23 — Phase-II G1 Biogen Idec 2 99% -0.767 158 ['135273044', '160698505', '404770124', '472386538', '474488739', '474489089', '498138006', '505778352', '513905275'] IDEC-152;IDEC152; IDEC 152;ST-152;ST152;ST 152
A4DAB162 Lumretuzumab ERBB3/HER3 — Phase-I/II G1 Roche 1 100% -0.6726 502 ['318464639', '347911360', '381127466', '472407344', '474488740', '474489087', '498152580', '505795858'] RG-7116;RG7116;RG 7116;RO-5479599;RO5479599;RO 5479599
A4DAB175 Lunsekimig2 TSLP;ALB — Phase-II non-canonical Sanofi 1 95-98% -0.7529 1488 ['485665265', '494430859'] SAR443765;SAR-443765
A4DAB163 Luvagrobart NGF — Phase-I G1 Akeso Biopharma 1 95-98% -0.624 1489 ['485666111', '494431299'] AK115;AK-115
A4DAB164 Maftivimab Zaire Ebolavirus Glycoprotein — Preregistration G1 Regeneron Pharmaceuticals 3 100% -0.5092 677 ['381609201', '404720351', '472407655', '480403145', '481988008', '505796173', '508534650', '513907217'] REGN 3479;REGN-3479;REGN3479;INMAZEB (combination with Atoltivimab and Odesivimab)
A4DAB165 Maridebart GIPR — Phase-II G1 Amgen 1 100% -0.7169 1407 ['478838469', '485483299', '485511874', '494430975'] AMG-133;AMG133;AMG 133;MariTide
A4DAB166 Masavibart SARS-CoV-2 Spike RBD — Approved G1 Regeneron Pharmaceuticals 5 100% -0.6336 1267 ['461453571', '472424444', '476262114', '476269250', '479821113', '513907218'] ZRC-3308A7;ZRC3308A7;ZRC 3308A7;ZRC-3308;ZRC3308;ZRC 3308
A4DAB167 Matuzumab EGFR/ERBB1/HER1 — Phase-II G1 ImClone Systems 6 100% -0.7071 39 ['135314357', '160671567', '347909947', '348986850', '387060161', '468800474', '472219701', '472418970', '481155372', '486486877', '488214711', '505057022', '505806396', '519930739'] EMD 72000;EMD-72000;EMD72000
A4DAB168 Melredableukin Non-Binding — Phase-II G1 Roche 3 99% -0.7106 None RG-7835;RG7835;RG 7835;RO-7049665;RO7049665;RO 7049665
A4DAB169 Metelimumab TGFB1 — Phase-II G4 Cambridge Antibody Technology 5 100% -0.7082 186 ['135320437', '160671619', '472407427', '474488741', '474489084'] CAT-192;CAT192;CAT 192
A4DAB170 Mevonlerbart Fel d 1 — Phase-III G4 Regeneron 2 100% -0.6969 1332 ['471299213', '472420380', '485483313', '485511886', '494431037'] REGN-1909;REGN1909;REGN1908-1909 (cocktail with Freneslerbart)
A4DAB171 Mosunetuzumab CD3E;MS4A1/CD20 Cancer Approved G1 Genentech 1 95-98% -0.6659 760 ['381128154', '404720369', '404772861', '472418928', '479821089', '481155458', '483928771', '498149583', '505056118'] BTCT 4465A;BTCT-4465A;RG7828;RG-7828;RG 7828;RO7030816;RO-7030816;RO 7030816
A4DAB172 Motavizumab Respiratory Syncytial Virus Glycoprotein F Infectious diseases Phase-III G1 MedImmune 15 100% -0.6921 73 ['135343079', '160671958', '349239992', '404770192', '472220430', '472397570', '472435535', '472440387', '482567225', '486370160', '505815268'] MEDI-524;MEDI 524;MEDI524;Numax;Rezield
A4DAB173 Muromonab CD3E — Approved (withdrawn) G2a Cancer Research UK 1 100% -0.7568 None ['46507837', '103771420', '472422762', '472435494', '472439862', '481155587', '498153009', '504687574'] Zolimomab
A4DAB174 Natalizumab ITGA4/CD49D Immune-mediated / inflammatory disorders Approved G4 Biogen 4 99% -0.7352 75 ['46505849', '50069162', '103771320', '135314782', '178103204', '329976990', '354355048', '402354775', '402355924', '440790360', '472207180', '472399420', '472677714', '481101759', '485727148', '488221355', '496156076', '496720466', '498149682', '505238003', '507700823', '508644822', '513262136', '513686217', '519958020', '521868416'] AN 10022;AN10022;AN-10022;AN 100226;AN-100226;AN100226;Antegren;BG-00002;BG 00002;BG00002;BG-0002;BG0002;BG 0002;BG2;BG-2;BG 2;Tysabri
A4DAB175 Navenibart KLKB1 Cardiovascular / hemostasis disorders Phase-II G1 Astria Therapeutics Inc 1 100% -0.7529 1579 ['485664157', '520376843'] STAR-0215;STAR0215;STAR 0215
A4DAB176 Navivumab Influenza A HA — Preclinical G1 Celltrion 9 100% -0.7116 551 ['381127440', '472408210', '480403168', '481988031', '513907235'] CT-P23;CT P23
A4DAB177 Necitumumab EGFR/ERBB1/HER1 Cancer Approved G1 ImClone Systems 13 100% -0.6425 294 ['135263756', '160698797', '249565770', '347910462', '472264654', '472398104', '481101761', '481155522', '483764323', '483765022'] IMC-11F8;IMC 11F8;IMC11F8;LY 3012211;LY3012211;LY-3012211;Portraza;Portrazza
A4DAB178 Nesfrotamig ERBB2/CD340/HER2;TNFRSF9/CD137/4-1BB — TBC G1;non-canonical TBC 60 100% -0.6964 1754 ['507432678'] TBC
A4DAB179 Nimotuzumab EGFR/ERBB1/HER1 Cancer Approved G1 Biocon Biopharmaceuticals 1 99% -0.7451 76 ['135356483', '160698394', '249565669', '349341271', '404770141', '461629175', '463565368', '472402092', '486348040', '488222554', '498127495', '505186985', '505850081'] DE-766;DE766;DE 766;KI-0501;KI0501;KI 0501;KI-501;KI 501;KI501;KI-0502;KI0502;KI 0502;KI-502;KI502;KI 502;OSAG101;OSAG-101;OSAG 101;Taixinsheng;TheraCIM;Theraloc;VECTHIX
A4DAB180 Nipocalimab FCGRT/FcRn Immune-mediated / inflammatory disorders Preregistration G1 Momenta 2 95-98% -0.7032 1020 ['385610257', '440234683', '472419996', '481155570', '498145564', '505057000', '505850122', '507510720', '513757561'] JNJ 80202135;JNJ-80202135;JNJ80202135;M 281;M-281;M281
A4DAB181 Nirsevimab Respiratory Syncytial Virus Infectious diseases Approved G1 AIMM Therapeutics 15 100% -0.641 853 ['381128205', '404720251', '472418861', '480403174', '481988037', '483928786', '508534155', '513905715'] MEDI 8897;MEDI-8897;MEDI8897;SP 0232;SP0232;SP-0232;SP-232;SP232;SP 232
A4DAB182 Nivolumab PDCD1/CD279/PD1 Cancer Approved G4 Aduro BioTech 4 100% -0.7559 424 ['135341610', '160698453', '178103907', '347910393', '349494907', '354355034', '384647092', '385327549', '387061103', '469753496', '472217544', '472403414', '475546929', '481101762', '481155336', '488222681', '496156066', '496739869', '498214778', '508644823', '513259915', '519875309'] BMS-936558;BMS936558;BMS 936558;MDX-1106;MDX1106;MDX 1106;ONO-4538;ONO4538;ONO 4538;OPDIVO;OPDUALAG (combination of Nivolumab and Relatlimab)
A4DAB183 Nurulimab CTLA4/CD152 Cancer Phase-I G1 Biocad 11 99% -0.66 960 ['402426098', '440234827', '472421699', '480403177', '481988040', '485206113'] BCD-145;BCD145;BCD 145
A4DAB184 Obinutuzumab MS4A1/CD20 Cancer Approved G1 GLYCART Biotechnology 5 100% -0.6898 238 ['135332744', '160682610', '178103523', '347910388', '384647096', '385327553', '387060188', '440798422', '459140318', '472264655', '472422594', '481101766', '481155382', '488412712', '498123658', '513905828'] Afutuzumab;GA-101;GA101;GA 101;Gazyva;Gazyvaro;R-7159;R 7159;R7159;RG 7195;RG-7159;RG7159;RO-5072759;RO5072759;RO 5972759
A4DAB185 Ociperlimab TIGIT/WUCAM/VSTM3 Cancer Phase-III G1 BeiGene 9 100% -0.6955 1080 ['433770649', '442064789', '472422495', '480403180', '481988043', '498143614', '505851320'] BGB-A1217;BGB A1217;WCD-118;WCD118;WCD 118
A4DAB186 Ocrelizumab MS4A1/CD20 Immune-mediated / inflammatory disorders Approved G1 Biogen 1 95-98% -0.6659 227 ['135357140', '160698363', '223365915', '347911266', '472264656', '472386062', '481101767', '481155374', '483558691', '483559307', '517704478'] Ocrevus;PRO 70769;PRO-70769;PRO70769;R 1594;R1594;R-1594;RG 1594;RG-1594;RG1594;RO4964913;RO-4964913;RO 4964913
A4DAB187 Odesivimab Zaire Ebolavirus Glycoprotein — Approved G1 Regeneron Pharmaceuticals 3 100% -0.5092 961 ['381608746', '404719778', '472407781', '480403181', '481988044', '505852078', '508534651', '513907260'] REGN 3471;REGN3471;REGN-3471;INMAZEB (combination with Atoltivimab and Maftivimab)
A4DAB188 Ofatumumab MS4A1/CD20 Cancer Approved G1 Genmab 3 100% -0.701 194 ['103771534', '135302238', '178103384', '329976991', '347910355', '349995626', '387060162', '440790866', '464013613', '468568984', '472264657', '472399120', '481101769', '481155375', '486382384', '488413003', '498129214', '505187026', '508534104'] Arzerra;GSK-1841157;GSK1841157;;GSK 1841157;Kesimpta;OMB-157;OMB157;OMB 157
A4DAB189 Ogalvibart SARS-CoV-2 Spike RBD — Phase-II/III G1 National Institute of Allergy and Infectious Diseases 3 100% -0.6391 1271 ['461453495', '472423988', '476000809', '476262116', '476269252', '513907261'] C-135-LS;BMS-986414;BMS 986414;BMS986414
A4DAB190 Olokizumab IL6 Immune-mediated / inflammatory disorders Approved G4 R-Pharm 2 100% -0.7488 353 ['160677293', '347911425', '381126049', '442878635', '472408106', '472435536', '472440386', '481155483', '498156024', '505852682'] Artlegia;CDP-6038;CDP6038;CDP 6038
A4DAB191 Omalizumab IGHE Immune-mediated / inflammatory disorders Approved G1 Dana-Farber Cancer Institute 30 100% -0.6853 77 ['46507002', '50067183', '103771317', '135293034', '178103472', '329976992', '354355054', '387060164', '440790867', '461629173', '463561825', '469690930', '472217555', '472386429', '475546925', '481101771', '481155406', '488413109', '496156067', '498142439', '508644824', '519839987'] IGE25;IGE-25;IGE 25;Olizumab;XOLAIR
A4DAB192 Omburtamab B7H3/CD276 Cancer Preregistration G1 Memorial Sloan-Kettering Cancer Center 1 100% -0.7735 855 ['381128149', '404719716', '472420141', '472435498', '472439868', '481155541', '498149659', '505852690'] OMBLASTYS
A4DAB193 Onartuzumab MET/HGFR Cancer Phase-III G1 Chugai Pharmaceutical 1 100% -0.7267 368 ['135324888', '160693418', '310264746', '347911234', '472390563', '472439123', '472441256', '505852702', '513905865', '519974962'] 5D5;MetMAb;OA-5D5;PRO-143966;PRO 143966;PRO143996;RG-3638;RG3638;RG 3638;RO-5490258;RO5490258;RO 5490258
A4DAB194 Ontamalimab MADCAM1 Immune-mediated / inflammatory disorders Phase-III G2 Pfizer 2 100% -0.7058 785 ['160682419', '328083443', '381128284', '404772730', '472406628', '476262744', '476269352'] PF-00547659;PF00547659;PF-547659;PF547659;SHP-647;SHP647;SHP 647;TAK-647;TAK647;TAK 647
A4DAB195 Opicinumab LINGO1 — Phase-II G1 Biogen Idec 1 100% -0.7376 557 ['310264704', '312467772', '381127358', '404772404', '472406660', '480403196', '481988059', '498152889', '505852728'] BIIB-033;BIIB033;BIIB 033;BIIB-33;BIIB33;BIIB 33
A4DAB196 Orilanolimab FCGRT/FcRn — Phase-II G4 Syntimmune 1 100% -0.7297 854 ['381128248', '404720518', '404772743', '472419735', '480403204', '481988067', '498148259'] ALXN 1830;ALXN1830;ALXN-1830;SYNT-001;SYNT001;SYNT 001;SYNT-1;SYNT1;SYNT 1;SYNT1001;SYNT-1001;SYNT 1001
A4DAB197 Osocimab F11 — Phase-II G1 Bayer HealthCare 1 99% -0.7098 857 ['381128246', '404720319', '404772268', '440816735', '472420951', '480403207', '481988070'] BAY-121379;BAY121379;BAY 121379
A4DAB198 Otilimab CSF2 Immune-mediated / inflammatory disorders Phase-III G1 GlaxoSmithKline 6 99% -0.6847 189 ['160682411', '381127828', '404770186', '434122192', '472419226', '480403208', '481988071', '505852917', '513905885'] GSK-3196165;GSK3196165;GSK 3196165;GSK165;GSK-165;GSK 165;MOR-103;MOR 103;MOR103
A4DAB216 Ozoralizumab TNF/TNFA;ALB Immune-mediated / inflammatory disorders Approved non-canonical Ablynx 1 100% -0.6573 382 ['160704161', '340590268', '347911269', '381126410', '472423473', '480403209', '481988072', '517689396'] ATN-103;ATN103;ATN 103;PF-5230896;PF5230896;PF 5230896;TS-152;TS152;TS 152
A4DAB199 Palivizumab Respiratory Syncytial Virus Glycoprotein F Infectious diseases Approved G1 MedImmune 1 99% -0.6878 79 ['46506637', '50069681', '103771316', '135347038', '329976993', '440790877', '472217551', '472423423', '481101776', '482566891', '486464920', '498149776', '505056132', '519915427'] MEDI-493;MEDI493;MEDI 493;Synagis
A4DAB200 Palverafusp VEGF — Phase-I/II G1 ImmuneOnco Biopharma 6 100% -0.6556 None IMM-2510;IMM2510;IMM 2510
A4DAB201 Pamlectabart TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E — Phase-I/II G1 Heidelberg Pharma AG 3 100% -0.6924 1690 ['507427879', '520377225'] J22.9;HDP-101;HDP 101;HDP101;HDM-2027;HDM 2027;HDM2027
A4DAB202 Panitumumab EGFR/ERBB1/HER1 Cancer Approved G2 Amgen 4 100% -0.6884 196 ['46505063', '50070211', '91145251', '103771525', '135300957', '178103465', '329976994', '354355055', '387060159', '440790881', '441072529', '464013599', '468568986', '468800479', '472264659', '472422803', '481101778', '481155377', '485727436', '488413774', '508644826', '519825823'] ABX-EGF;E7.6.3;Panitumab;Vectibix
A4DAB203 Paridiprubart TLR4/CD284 Immune-mediated / inflammatory disorders Phase-III G1 Edesa Biotech 16 100% -0.6864 1275 ['461454360', '472407724', '476000898', '476262117', '476269253', '507750348'] EB 05;EB05;EB-05;EB 5;EB-5;EB5;EB-07;EB07;EB-07;EB-7;EB7;EB 7;NI-0101;NI 0101;NI0101;NI-101;NI101;NI 101
A4DAB204 Pateclizumab LTA — Phase-II G1 Genentech 5 100% -0.6907 383 ['160682612', '363894148', '381126562', '404772441', '472397390', '485483283', '485511861', '505854663'] MLTA3698A;MLTA-3698A;MLTA 3698A;PRO283698;PRO-283698;PRO 283698;RG7416;RG-7416;RG 7416
A4DAB205 Pembrolizumab PDCD1/CD279/PD1 Cancer Approved G4 Aduro BioTech 11 100% -0.6511 472 ['187051801', '194140938', '347910395', '354355033', '377483934', '384647091', '385327548', '387061105', '469499371', '469691028', '472217543', '472404427', '475546924', '481101797', '481155337', '488414049', '496740296', '498097597', '508644829', '519903473'] MK-3475;MK3475;MK 3475;Keytruda;Lambrolizumab;SCH-900475;SCH900475;SCH 900475
A4DAB206 Pemivibart SARS-CoV-2 Spike RBD — Approved G1 Invivyd 1 95-98% -0.6331 1498 ['485664487', '505855119', '520377482'] VYD222;VYD-222;VYD 222
A4DAB207 Pertuzumab ERBB2/CD340/HER2 Cancer Approved G1 Chugai Pharmaceutical 17 100% -0.6744 80 ['50069677', '135348342', '136926963', '178101741', '329976972', '347910348', '349020482', '354355049', '384647098', '385327555', '387061213', '441080425', '468817967', '472218185', '472422729', '472677715', '481101798', '481155407', '486341070', '488414453', '496156077', '498137358', '505187042', '508644828', '513260811', '519908957'] R-1273;R1273;R 1273;RG-1273;RG 1273;RG1273;RO-4368451;RO4368451;RO 4368451
A4DAB208 Pexelizumab C5 — Phase-III non-canonical Stanford University 2 99% -0.7165 81 ['135313425', '160693004', '347909855', '472398204', '476264169', '476270780', '505856386', '513905956'] 5G1.1
A4DAB209 Pinatuzumab SIGLEC2/CD22 — Phase-II G1 Genentech 1 99% -0.742 None ['472435552', '472440353', '481155543', '513253358'] DCDT-2980S;DCDT29080S;DCDT 29080S;FCU-2703;FCU2703;FCU 2703;RG-7593;RG7593;RG 7593;RO-5541072;RO5541073;RO 5541073
A4DAB228 Podentamig1 TNFRSF17/BCM/BCMA/CD269/TNFRSF13A;ALB — Phase-I non-canonical Harpoon Therapeutics 8 95-98% -0.6813 1589 ['496141557', '520378257'] HPN-217;HPN 217;HPN217
A4DAB210 Ponezumab APP — Phase-II G2 Rinat Neuroscience 2 100% -0.6488 369 ['135354668', '160687959', '404772575', '472422736', '472435539', '472440379', '481155528', '505863164'] PF-04360365;PF04360365;PF-4360365;PF4360365;RN 1219;RN-1219;RN1219
A4DAB230 Porustobart CTLA4/CD152 — Phase-II G1 Harbour Biomed 2 100% -0.7146 1368 ['471298931', '474492459', '476000927'] HBM-4003;HBM4033;HBM 4033;HCAb-4003-2
A4DAB211 Porgaviximab Zaire Ebolavirus Glycoprotein — Phase-II G1 Mapp Biopharmaceutical 3 99% -0.6714 727 ['374364165', '381127997', '472408628', '476262940', '476269579', '513907280'] c2G4-N;Zmapp
A4DAB212 Prezalumab ICOSLG — Phase-II G2 Amgen 2 100% -0.7146 598 ['160709221', '381127586', '472409526', '474488758', '474489160', '498152194'] AMG-557;AMG557;AMG 557;B7RP-1;MEDI-5872;MEDI 5872;MEDI5872
A4DAB213 Pulocimab KDR/CD309/VEGFR2 Cancer Phase-III G1 Akeso Biopharma 3 99% -0.635 1194 ['443565664', '461565711', '472424599', '480403215', '481988078', '513757576'] AK-109; AK109;AK 109
A4DAB214 Pumitamig1 VEGFA — TBC G1 TBC 8 100% -0.6784 None TBC
A4DAB235 Pumitamig2 PDL1/CD274 — TBC non-canonical TBC 1 100% -0.6796 None TBC
A4DAB215 Quilizumab IGHE — Phase-II G1 Genentech 4 100% -0.6604 406 ['160698538', '310264776', '381126678', '404772614', '472401245', '474488746', '474489074', '505867784'] MEMP-1972A;MEMP1972A;MEMP 1972A;RG-7449;RG7449;RG 7449
A4DAB216 Ralpancizumab PCSK9 — Phase-I G2 Pfizer 1 95-98% -0.6573 484 ['194147765', '381127284', '472422773', '480403221', '481988084'] PF-05335810;PF05335810;PF-5335810;PF5335810;RN 317;RN-317;RN317
A4DAB217 Ramucirumab KDR/CD309/VEGFR2 Cancer Approved G1 Dyax 3 100% -0.635 295 ['131408697', '135285364', '160666631', '178103962', '347910183', '354355038', '384647101', '385327559', '387060193', '459140361', '469690935', '472264660', '472397511', '475546934', '476272603', '481101818', '481149735', '488293647', '496156069', '496740909', '505242573', '513253724', '519905010'] Cyramza;IMC-1121;IMC1121;IMC 1121;IMC-1C11;IMC1C11;IMC 1C11;LY-3009806;LY 3009806;LY3009806;Ramcilumab;Ramsilmab;Ramsilomab;Ramsylmab;Ramsylumab;Sairamza;Silamza
A4DAB218 Ranibizumab VEGFA Ophthalmic disorders Approved G1 Genentech 8 100% -0.6784 84 ['46506960', '50070212', '103771523', '135321230', '178103385', '329976995', '348994288', '438447952', '441072530', '445534060', '461629174', '463561824', '468804000', '472217550', '472397235', '481101819', '481155378', '488418370', '508644634', '513262135', '519837115'] ACCENTRIX;RG-3645;RG3645;RG 3645;RG-6321;RG6321;RG 6321;Susvimo
A4DAB219 Ravagalimab TNFRSF5/CD40 — Phase-II G1 AbbVie 8 100% -0.7183 806 ['381128231', '404719315', '472420134', '480403226', '481988089', '504705726', '505871107'] ABBV 323;ABBV-323;ABBV 323;PR 1629977;PR-1629977;PR1629977
A4DAB220 Ravulizumab C5 Immune-mediated / inflammatory disorders Approved G2 Alexion Pharmaceuticals 2 99% -0.7165 674 ['374364184', '381118878', '381128036', '404770733', '472415839', '476262699', '476269306', '483928739', '498150315', '513906176'] ALXN 1210;ALXN-1210;ALXN1210;ALXN 1810;ALXN-1810;ALXN1810;Ultomiris
A4DAB221 Regdanvimab SARS-CoV-2 Spike RBD Infectious diseases Approved G1 Celltrion 1 100% -0.7158 1109 ['434150988', '434321767', '442064648', '472422727', '476262680', '476269282', '505874987', '513907295'] CT P59;CT-P59;IN-006;IN006;IN 006;IN-6;IN6;IN 6;Regkirona;T-P59
A4DAB222 Relatlimab LAG3/CD223 Cancer Approved G4 Bristol-Myers Squibb 2 99% -0.6896 781 ['336446922', '374363887', '381127923', '404772299', '472419200', '472435497', '472439867', '488418527', '498151132', '505875146'] BMS 986016;ONO-4482;BMS986016;BMS 986016;ONO 4482;ONO4482
A4DAB223 Remtolumab IL17A;TNF/TNFA — Phase-II G1;G1 Abbott Laboratories 6 100% -0.6716 517 ['340590227', '381127991', '404720166', '404772568', '472409037', '476262969', '476269836', '513906197'] ABT-122;ABT122;ABT 122
A4DAB224 Renvistobart TIGIT/WUCAM/VSTM3 — Phase-II G1 Bristol-Myers Squibb 2 100% -0.6157 1425 ['404720502', '472411723', '485483333', '485511901'] BMS-986207;BMS 986207;BMS986207
A4DAB225 Ripertamab MS4A1/CD20 Cancer Approved G1 Sinocelltech 9 100% -0.6555 1027 ['405023378', '440234663', '472421855', '476264173', '476270785'] SCT-400;SCT400;SCT 400
A4DAB226 Rituximab MS4A1/CD20 Cancer Approved G1 Biogen 11 100% -0.6395 161 ['46505820', '50070184', '103771410', '135341754', '178103386', '319435463', '329976960', '348838049', '354355036', '365372203', '384647099', '385327556', '387061212', '441072531', '468746478', '469691030', '472186860', '472387480', '475546920', '481101830', '481155379', '488418835', '496156070', '496741027', '498150678', '508644831', '513259886', '519929088'] IDEC-102;IDEC102;IDEC 102;IDEC-C2B8;IDEC C2B8;RG 105;RG-105;RG105;Ristova;Rituxan;RO-452294;RO 452294;RO452294
A4DAB227 Romlusevimab SARS-CoV-2 Spike RBD — Phase-II/III G1 Brii Biosciences 2 99% -0.6074 1216 ['442064693', '443565775', '472423206', '480403245', '481988108', '513907303'] BRII-198;BRII198;BRII 198
A4DAB228 Rontalizumab IFNA1 — Phase-II G2 Chugai Pharmaceutical 8 100% -0.6813 327 ['135285221', '160687960', '340590270', '347911394', '472387820', '474488709', '474489044', '505879618', '513906243'] RhuMAB IFNalpha
A4DAB229 Rozanolixizumab FCGRT/FcRn Immune-mediated / inflammatory disorders Approved G4 UCB 1 100% -0.6976 642 ['354702273', '381127650', '404719939', '404772364', '461629178', '463599439', '472410164', '481155569', '483928629', '498151966', '500132552'] RYSTIGGO;UCB-7665;UCB7665;UCB 7665
A4DAB230 Rozibafusp ICOS/CD278 — Phase-II G2 Amgen 2 100% -0.7146 None AMG 570;AMG-570;AMG570;MEDI0700;MEDI-0700;MEDI 0700;MEDI700;MEDI-700;MEDI 700
A4DAB231 Runimotamab ERBB2/CD340/HER2;CD3E — Phase-I G1;G1 Genentech 60 100% -0.6964 1143 ['440235195', '442064687', '472419491', '485480363', '485517581'] BTRC-4017A;BTRC4017A;BTRC 4017A;RG-6194;RG6194;RG 6194;RO-7227780;RO7227780;RO 7227780
A4DAB232 Ruplizumab CD40LG/CD154 — Phase-II G1 Biogen 4 100% -0.7209 17 ['135337719', '160709140', '404770272', '472408190', '474488747', '474489071', '505879904', '513906257', '517704475'] BG 9588;BG-9588;BG9588
A4DAB233 Sabestomig PDCD1/CD279/PD1;HAVCR2/TIM3 — Phase-II G1;G1 AstraZeneca 2 99% -0.6859 1428 ['478838692', '494431265'] AZD7789;AZD-7789
A4DAB234 Sarilumab IL6R/CD126 Immune-mediated / inflammatory disorders Approved G1 Asahi Kasei Pharma Corp 1 100% -0.7434 400 ['160687628', '249565679', '347911238', '381126483', '406846983', '406850446', '472264661', '472400783', '481101845', '481155380', '518314158'] Kevzara;REGN-88;REGN88;REGN 88;SAR-153191;SAR153191;SAR 153191
A4DAB235 Sasanlimab PDCD1/CD279/PD1 Cancer Phase-III G4 Pfizer 1 100% -0.6796 969 ['381608931', '404720335', '472419313', '485482309', '485511949', '505880532'] PF-06801591;PF06801591;PF-6801591;PF6801591;RN-888;RN888;RN 888
A4DAB236 Satumomab TAG72 — Approved G1 Cytogen Corporation 2 99% -0.822 138 ['131279415', '160682280', '381123755', '472219978', '472407524', '513906282'] CYT 103;CYT-103;CYT103;CR103;CR-103;CR 103;OV103;OV-103;OV 103
A4DAB237 Secukinumab IL17A Immune-mediated / inflammatory disorders Approved G1 Beth Israel Deaconess Medical Center 2 100% -0.6758 326 ['135288104', '160677295', '249565758', '347910391', '348644151', '354355044', '387060192', '461629171', '463561821', '469690928', '472264664', '472402212', '475546923', '481101848', '481155328', '488421038', '496156071', '498154447', '507720775', '513686597'] AIN-457;AIN457;AIN 547;Cosentyx;KB-03303A;KB03303A;KB 03303A;KB3303A;KB-3303A;KB 3303A;Kosentikusu;NVP-AIN-457;Scapho
A4DAB238 Serplulimab PDCD1/CD279/PD1 Cancer Approved G4 Henlix Biotech 1 100% -0.6768 970 ['402426057', '440234555', '472419871', '473142883', '473143251', '498145082', '505880864', '507750429', '513906310'] HLX-10;HLX10;HLX 10
A4DAB239 Sifalimumab IFNA1 — Phase-II G1 Medarex 2 100% -0.6825 322 ['135309420', '160682615', '249565937', '347911377', '472220432', '472422558', '472435542', '472440374', '481155533', '498156033', '505880970'] MDX-1103;MDX1103;MDX 1103;MEDI-545;MEDI545;MEDI 545
A4DAB240 Simaravibart SARS-CoV-2 Spike RBD Infectious diseases Phase-II/III G1 Toscana Life Sciences 8 100% -0.5936 1376 ['471299386', '474493219', '485480791', '485517577'] MAD-0004J08;MAD0004J08;MAD 0004J08;MAD-4J08;MAD4J084;MAD 4J08
A4DAB241 Sipavibart SARS-CoV-2 Spike RBD Infectious diseases Preregistration G1 AstraZeneca 6 100% -0.6561 1510 ['474494761', '494430965', '513757590'] AZD3152;AZD-3152
A4DAB242 Solanezumab APP Neurological disorders Phase-III G1 Eli Lilly 2 99% -0.6564 298 ['135274944', '160704163', '178103514', '347911237', '349503845', '472406764', '474488749', '474489069', '476293841', '481150519', '488294107', '505883989'] LY-2062430;LY 2062430;LY206430
A4DAB243 Solnerstotug VSIR/VISTA/B7H5/PD1H/SISP1 — Phase-I/II G1 Sensei Biotherapeutics 2 99% -0.6834 1673 ['507428735', '520377001'] SNS-101;SNS 101;SNS101
A4DAB244 Sonavibart Influenza A HA — Phase-II G1 Humabs BioMed 9 100% -0.6464 1597 ['496141524', '520377801'] MEDI8852;MEDI-8852;MEDI 8852
A4DAB269 Sonelokimab1 IL17A;ALB — Phase-III non-canonical Ablynx 4 95-98% -0.6823 971 ['385612250', '402425678', '404719351', '472419685', '476262731', '476269339', '481155518'] ALX 0761;ALX-0761;ALX0761;ALX-761;ALX761;ALX 761;M 1095;M1095;M-1095;MSB-0010841;MSB 0010841;MSB0010841;MSB10841;MSB-10841;MSB 10841;Sonelokinab
A4DAB245 Sotrovimab SARS-CoV-2 Spike RBD Infectious diseases Approved G1 GlaxoSmithKline 57 99% -0.6827 1110 ['434321768', '434370441', '442064750', '472422617', '483928823', '505057015', '513907372'] GSK-4182136;GSK 4182136;GSK 4182136;VIR-7831;VIR 7831;VIR7831;WBP 2275;WBP-2275;WBP2275
A4DAB246 Sovipostobart CTLA4/CD152 — Phase-II G1 CytomX Therapeutics 11 100% -0.66 1430 ['478838272', '485483334', '485511902', '494430985'] BMS-986249;BMS 986249;BMS986249
A4DAB247 Spesolimab IL36RN Immune-mediated / inflammatory disorders Approved G1 Boehringer Ingelheim 1 100% -0.7604 860 ['381128270', '404719820', '472319291', '472419473', '476262730', '476269338', '481155453', '483928962', '498147763', '500131935'] BI 655130;BI655130;BI-655130;SPEVIGO
A4DAB248 Sudubrilimab PDL1/CD274 — Phase-II G1 Zhejiang Hisun Pharmaceutical 6 95-98% -0.6556 1145 ['440235227', '472425212', '476263226', '476269987'] HS636;HS-636;HS 636
A4DAB249 Sutacimig F7a/F7A/FVIIa/FVIIA;TREML1/GLTL1825/PRO3438/TLT-1/TLT1 — Phase-I/II G4;G4 Hemab 6 100% -0.6891 1700 ['507429523', '520377709'] HMB001;HMB-001;HMB 001
A4DAB250 Suvizumab HIV-1 gp120 — Phase-I G1 Kaketsuken 1 100% -0.6918 330 ['160698802', '381125776', '472407503', '480403090', '481987978', '513907379'] KD-247;KD247;KD 247
A4DAB251 Suvratoxumab Staphylococcus aureus Toxin A Infectious diseases Phase-III G1 Biosynexus 2 100% -0.7009 716 ['374364067', '381127801', '404772611', '472405028', '496703331', '505056134', '505885993'] AR-320;AR320;AR 320;MEDI-4893;MEDI4893;MEDI 4893
A4DAB252 Talacotuzumab IL3RA/CD123 Cancer Phase-II G1 CSL 2 100% -0.7023 754 ['381128089', '404719346', '404772246', '472419168', '476262729', '476269337', '498150096'] CSL-362;CSL362;CSL 362;JNJ 473;JNJ473;JNJ473;JNJ 56022473;JNJ56022473;JNJ-56022473
A4DAB253 Talquetamab GPRC5D;CD3E Cancer Approved G4;G4 Genmab 1 100% -0.7404 973 ['402425660', '440234734', '472420911', '473153828', '476262728', '476269336', '483928983', '498145303', '513906409'] JNJ 64407564;JNJ64407564;JNJ-64407564;JNJ-7564;JNJ7564;JNJ 7564;TALVEY
A4DAB254 Tamrintamab DPEP3 — Phase-I G1 Stemcentrx 2 100% -0.6566 905 ['381608702', '472408684', '476262836', '476269496'] SC-003;SC003;SC 003;SC-3;SC3;SC 3;SC34.28ss1
A4DAB255 Tamtuvetmab CD52 — Unknown G2 Aratana Pharmaceuticals 4 95-98% -0.6596 594 ['318464641', '381127699', '472407791', '476262898', '476269494'] AT005;AT-005;AT 005;AT5;AT-5;AT 5
A4DAB256 Tanezumab NGFB Neurological disorders Phase-III G2 Rinat Neuroscience 1 100% -0.624 230 ['135325228', '160682307', '252166625', '347911318', '349404150', '472422556', '472435544', '472440370', '482588855', '498125446', '505886998'] PF-04383119;PF04383119;PF-4383119;PF4383119;RI-624;RI624;RI 624;RN-624;RN624;RN 624
A4DAB257 Tarcocimab VEGFA — Phase-III G1 Kodiak Biosciences 8 100% -0.6784 1188 ['443566250', '472425497', '476262895', '476269491', '494431223'] KSI-301;KSI301;KSI 301
A4DAB283 Tarperprumig ALB;CFP — Phase-II non-canonical Alexion Pharmaceuticals 8 100% -0.5043 1324 ['471299383', '474494091', '494430941'] ALXN-1820;ALXN1820;ALXN 1820
A4DAB258 Tazlestobart CTLA4/CD152 — TBC G1 TBC 13 100% -0.6732 1598 ['496142818', '520377101'] TBC
A4DAB259 Tegoprubart CD40LG/CD154 — Phase-II G1 ALS Therapy Development Institute 4 100% -0.7209 1433 ['440234811', '472420334', '485483336', '485511905'] AT-1501;AT1501;AT 1501
A4DAB260 Teneliximab TNFRSF5/CD40 — Phase-II G1 Bristol-Myers Squibb 1 100% -0.7277 276 ['135274809', '160676923', '472399231', '474488753', '474489065', '498139709'] Chi220
A4DAB261 Teropavimab HIV-1 gp120 CD4bs — Phase-II G1 Gilead 29 100% -0.7814 1209 ['443565964', '472419803', '476001010', '476264145', '476270752', '505887337'] 3BNC 117;3BNC-117;GS-5423;GS 5423;GS5423;Lafuvitug
A4DAB262 Tezepelumab TSLP Immune-mediated / inflammatory disorders Approved G2 Amgen 1 100% -0.7077 573 ['310264714', '318464472', '381127637', '404772532', '472404557', '476262700', '476269307', '483928625', '498151999', '513906464'] AMG 157;AMG-157;AMG157;MEDI-9929;MEDI9929;MEDI 9929;Tezspire
A4DAB263 Tibulizumab TNFSF13B/CD257/BAFF;IL17A — Phase-I G4;G4 Eli Lilly 1 95-98% -0.6849 776 ['374363834', '381128114', '384403631', '404772296', '472415124', '476262884', '476269451'] LY-3090106;LY3090106;LY 3090106;ZB-106;ZB106;ZB 106
A4DAB264 Tilogotamab TNFRSF10B/CD262/DR5/TRAILR2 — Phase-I/II G1 Genmab 2 99% -0.7204 1035 ['405023319', '472421517', '476262880', '476269424'] GEN-1029;GEN1029;GEN 1029
A4DAB265 Tilrekimig2 TSLP — Phase-II G1 Pfizer 1 95-98% -0.7077 1787 ['507427835', '520378100'] PF-07275315;PF 07275315;PF07275315
A4DAB266 Timigutuzumab ERBB2/CD340/HER2 — Approved G1 Roche 60 100% -0.6964 739 ['381127916', '472414887', '476262879', '476269423'] GEXMab73;GEXMab-73;GEXMab 73
A4DAB267 Timcevibart SARS-CoV-2 Spike RBD — TBC G1 TBC 1 100% -0.6086 1512 ['485666525'] TBC
A4DAB268 Tiragolumab TIGIT/WUCAM/VSTM3 Cancer Phase-III G1 Genentech 3 100% -0.6614 765 ['381128164', '404719438', '472419169', '481155456', '498149479', '505056138', '505894150', '517704472'] MTIG-7192A;MTIG7192A;MTIG 7192A;RG-6058;RG6058;RG 6058;RO 7092284;RO-7092284;RO7092284
A4DAB269 Tislelizumab PDCD1/CD279/PD1 Cancer Approved G4 BeiGene 4 100% -0.6823 757 ['340590223', '377483943', '404720526', '404772367', '472419174', '488425221', '498149908', '505056124', '505894154', '508534479'] BGB-A317;BGB A317;TEVIMBRA;Tilelizumab;VDT-482;VDT 482;VDT482
A4DAB270 Tixagevimab SARS-CoV-2 Spike RBD — Approved G1 AstraZeneca 19 100% -0.7244 1111 ['434321765', '434370464', '442064857', '472423072', '476262877', '476269421', '483928821', '513907388', '517704485'] COV2-2196;COV2 2196;AZD-8895;AZD8895;AZD 8895;AZD7442 (combination of cilgavimab and tixagevimab);AZD-7442 (combination of cilgavimab and tixagevimab);EVUSHELD (combination of cilgavimab and tixagevimab)
A4DAB271 Tocilizumab IL6R/CD126 Immune-mediated / inflammatory disorders Approved G1 Assistance Publique Hopitaux de Paris 1 100% -0.6933 96 ['104253153', '135345962', '178103463', '329976997', '347910344', '349016747', '354355060', '385326041', '385327557', '387061215', '405092064', '469690931', '472264665', '472385906', '475546922', '481155381', '485726264', '488425338', '496156075', '498137477', '508644835', '513262009', '517913830', '519973228'] Atlizumab;R-1569;R1569;R 1569;RG-1569;RG1569;RG 1569;RO4877533;RO-4877533;RO 4877533;RoActemra
A4DAB272 Tomuzotuximab EGFR/ERBB1/HER1 — Phase-II G1 Glycotope 70 99% -0.6741 738 ['381127867', '404720131', '404772616', '472414879', '476262667', '476269280'] GT-MAB 5.2-GEX
A4DAB273 Toripalimab PDCD1/CD279/PD1 Cancer Approved G4 Fudan University 1 100% -0.6628 863 ['381128166', '404719502', '404772487', '472419518', '481155597', '485206110', '498149430', '505056137', '505894547'] CHS-007;CHS007;CHS 007;CHS-7;CHS7;CHS 7;JS 001;JS001;JS-001;JS1;JS-1;JS 1;SO-001;SO 001;SO001;SO1;SO-1;SO 1;TAB-001;TAB001;TAB 001;TAB1;TAB-1;TAB 1;Tripleitriumab;Triprizumab;Tuoyi
A4DAB274 Tovecimig VEGFA Cancer Phase-II/III G1;non-canonical ABL Bio 8 100% -0.6784 1654 ['507428328', '520378463'] ABL-001;ABL 001;ABL001;CTX-009;CTX 009;CTX009;ES 104;ES-104;ES104;HD-B001A;NOV1501;NOV-1501;NOV 1501;TR-009;TR 009;TR009
A4DAB275 Trabikibart CSF2RB/CD131/IL3RB/IL5RB — Phase-I G4 CSL 1 100% -0.7233 1435 ['478839002', '485483414', '485511916', '494430853'] CSL311;CSL-311
A4DAB276 Tralokinumab IL13 Immune-mediated / inflammatory disorders Approved G4 Cambridge Antibody Technology 2 100% -0.7049 171 ['135339998', '160687963', '249565681', '347911293', '472220896', '472404311', '481155562', '483928230', '498155768', '505056125', '508534094'] CAT-354;CAT354;CAT 354;Adbry;Adtralza;LP 016;LP016;LP-016;LP-16;LP16;LP 16
A4DAB277 Trastuzumab ERBB2/CD340/HER2 Cancer Approved G1 Roche 60 100% -0.6964 97 ['521856', '46507516', '50067185', '103771413', '135301230', '178101775', '319436173', '329976959', '348480210', '348846999', '350080044', '354355040', '365372316', '375567394', '387061211', '438447953', '440790663', '441072533', '445536532', '446503458', '468751929', '469691027', '472217545', '472399234', '472677712', '479831890', '480504414', '481101883', '481155341', '486299790', '488425953', '489770134', '496156072', '496210833', '497696778', '503640157', '507639450', '508644837', '513259656', '519902523'] Herceptin;4D5-8
A4DAB278 Tremelimumab CTLA4/CD152 Cancer Approved G2 AIO Studien gGmbH 3 100% -0.6508 248 ['135304002', '160698442', '252166672', '347911239', '469605945', '471144016', '471146373', '472399327', '481155347', '483929367', '498128052', '519842798'] CP-675;CP675;CP 675;CP-675206;CP 675206;CP675206;IMJUDO;Ticilimumab
A4DAB279 Trontinemab APP Abeta 1-40/42;TFRC/CD71 — Phase-II G1;G1 Roche 2 100% -0.6953 1286 ['461453731', '472420579', '476000870', '483558703', '483559431', '517688549'] RG-6102;RG6102;RG 6102;RO 7126209;RO7126209;RO-7126209
A4DAB280 Tusamitamab CEACAM5/CD66e — Phase-III G1 Sanofi-Aventis 1 100% -0.4896 1086 ['433770569', '472422421', '476001011', '481155577', '498143571', '505057006'] IBI-126;IBI126;IBI 126;SAR 701;SAR701;SAR-701;SAR-408701;SAR 408701;SAR408701
A4DAB281 Umesolerbart Bet v 1 — Phase-III G4 Regeneron 1 100% -0.6563 1333 ['471299149', '474492746', '476000826', '485483314', '485511887'] REGN5713-5714-5715 (combination of Atisnolerbart; Bremzalerbart; and Umesolerbart)
A4DAB282 Umizortamig1 EGFRvIII;CD3E — TBC non-canonical;G1 TBC 4 99% -0.6903 1343 ['471298885', '472319300', '474494634', '494431168'] TBC
A4DAB283 Upanovimab SARS-CoV-2 Spike RBD Infectious diseases Phase-II/III G1 Sinocelltech 8 95-98% -0.5043 1214 ['443566420', '461565857', '472425211', '476262859', '476269405'] SCTA-01;SCTA01;SCTA 01;SCTA-1;SCTA1;SCTA 1
A4DAB284 Urelumab TNFRSF9/CD137/4-1BB — Phase-II G4 Bristol-Myers Squibb 2 100% -0.6953 373 ['135357295', '160682619', '318164830', '347911279', '440798814', '472393043', '481155343', '498124040', '505897364'] BMS-663513;BMS663513;BMS 663513;BMS-66513;BMS66513;BMS 66513;ONO-4481;ONO4481;ONO 4481
A4DAB285 Ustekinumab IL12B/CLMFp40 Immune-mediated / inflammatory disorders Approved G1 Centocor Inc 2 100% -0.7062 172 ['103771533', '135302166', '178103467', '347910190', '349905851', '349984255', '354355053', '355433663', '377017835', '384647095', '385327552', '387060191', '440790971', '459142811', '469691025', '472217542', '472386393', '475546931', '477522405', '481101893', '481155329', '486347098', '488427388', '496156073', '497982764', '505187368', '519873421'] CNTO 1275;CNTO-1275;CNTO1275;TT-20;TT20;TT 20
A4DAB286 Utomilumab TNFRSF9/CD137/4-1BB Cancer Phase-II G2 Dana-Farber Cancer Institute 6 100% -0.5955 657 ['315661319', '318464561', '381127322', '404772553', '472407257', '488414511', '497983042', '505056126', '505897437'] PF-05082566;PF05082566;PF-5082566;PF5082566;PF-2566;PF2566
A4DAB287 Valanafusp INSR/CD220 — Phase-II G1 ArmaGen Technologies 3 99% -0.6909 None AGT-181;AGT181;AGT 181
A4DAB288 Vanucizumab ANGPT2;VEGFA — Phase-II G1;G1 Roche 12 100% -0.6882 500 ['312468109', '315661217', '347911315', '381127463', '472408703', '476262672', '476269274', '505897648', '513906586'] RG-7221;RG7221;RG 7221;RO-5520985;RO5520985;RO 5520985
A4DAB289 Vebanvibart SARS-CoV-2 Spike RBD — Phase-II G1 Sinovac Biotech 4 100% -0.5742 1607 ['496143293'] SA-55;SA 55;SA55;BD55-5514
A4DAB290 Velaprumig ALB;CD40LG/CD154 — TBC G1;non-canonical TBC 4 100% -0.7209 1740 ['507428198'] TBC
A4DAB291 Venanprubart BTLA/CD272 — Phase-II G4 Eli Lilly 1 100% -0.6681 1518 ['478838303', '494430926'] LY-3361237;LY3361237;LY 3361237
A4DAB292 Vesencumab NRP1 — Phase-I G1 Genentech 1 100% -0.6685 374 ['160666633', '381126585', '404772855', '472387951', '476262719', '476269328', '497983080', '505897752', '513906596'] M 1685A;M1685A;M-1685A;MNRP 1685A;MNRP-1685A;MNRP1685A;R 7347;R7347;R-7347;RG7347;RG-7347;RG 7347
A4DAB293 Verenafusp INSR/CD220 — Phase-II/III G1 GENERIUM Pharmaceuticals 3 99% -0.6909 None GNR-055;GNR055;GNR 055
A4DAB294 Vilastobart CTLA4/CD152 — Phase-I/II G1 Xilio Therapeutics 6 100% -0.7873 1521 ['485663941', '494431213'] XTX-101;XTX 101;XTX101
A4DAB295 Vislarafusp SIRPA — Phase-I/II G1 ImmuneOnco Biopharma 58 99% -0.6964 None IMM2902;IMM-2902;IMM 2902
A4DAB296 Vixticibart NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA — TBC G4 TBC 4 100% -0.6208 1608 ['496142618', '520378179'] TBC
A4DAB297 Vofatamab FGFR3/CD333 — Phase-I/II G1 BioClin Therapeutics 3 95-98% -0.6557 891 ['381126948', '404720590', '404772231', '472419471', '476262717', '476269326', '513906603'] B701;B 701;B-701;MFGR 1877A;MFGR-1877A;MFGR1877A
A4DAB298 Volagidemab GCCR/NR3C1 — Phase-II G2 Amgen 7 99% -0.7118 910 ['381608717', '404719898', '472407929', '476262716', '476269325', '505897970'] AMG-477;AMG477;AMB 477;REMD-477;REMD477;REMD 477
A4DAB299 Volrustomig CTLA4/CD152;PDCD1/CD279/PD1 Cancer Phase-III G1 AstraZeneca 3 100% -0.6508 1317 ['462764893', '472420293', '476000956'] MEDI-5752;MEDI5752;MEDI 5752
A4DAB300 Vonlerolizumab TNFRSF4/CD134/OX40 — Phase-II G1 Genentech 5 100% -0.7543 608 ['315661320', '374364247', '381127831', '472408746', '472435566', '472439864', '497983004'] MOXR-0916;MOXR0916;MOXR 0916;MOXR-916;MOXR916;MOXR 916;Pogalizumab;RG 7888;RG7888;RG-7888
A4DAB301 Vopikitug IL2RA/CD25 — Phase-I G1 Roche 1 100% -0.6414 1441 ['442064859', '472423545', '485483339', '485511908'] RG 6292;RG-6292;RG6962;RO 7296682;RO-7296682;RO7296682
A4DAB302 Vudalimab CTLA4/CD152;PDCD1/CD279/PD1 — Phase-II G1;G1 Xencor 11 95-98% -0.66 1083 ['433770790', '440234886', '472419961', '472435505', '472439881', '481155551', '497982906'] XmAb 717;XmAb717;XmAb-717;XmAb-20717;XmAb 20717;XmAb20717
A4DAB303 Xaluritamig STEAP1;CD3 Cancer Phase-III G1;non-canonical Amgen 1 100% -0.5728 1309 ['471299029', '474492365', '507750352'] AMG-509;AMG509;AMG 509
A4DAB304 Zanidatamab ERBB2/CD340/HER2;ERBB2/CD340/HER2 Cancer Approved G1;G1 Zymeworks 74 100% -0.6899 735 ['402425918', '442064711', '472418821', '476262713', '476269322', '504705446', '508534393'] ZW 25;ZW-25;ZW25
A4DAB305 Zemocimig F9a;F10 — TBC G4;G4 TBC 8 100% -0.7858 1741 ['507428646'] TBC
A4DAB306 Zenocutuzumab ERBB3/HER3;ERBB2/CD340/HER2 Cancer Approved G1;G1 Merus 3 100% -0.659 771 ['381128193', '404720332', '404772984', '472419170', '476262837', '476269383', '505900750', '507750283', '508534392'] MCLA-128;MCLA128;MCLA 128
A4DAB307 Zeripatamig IAP/CD47;CD19 — Phase-I G1;G1 TG Therapeutics 2 100% -0.69 1325 ['442064691', '471299000', '472423077'] TG-1801;TG1801;TG 1801
A4DAB308 Zinlirvimab HIV-1 gp120 V3 — Phase-II G1 Gilead 49 100% -0.5725 1290 ['404720462', '461454354', '472419776', '483558685', '483559434', '505901094', '513907433'] 10-1074;10 1074;GS-2872;GS2872;GS 2872
A4DAB309 Zuberitamab MS4A1/CD20 Cancer Phase-II G1 Zhejiang Hisun Pharmaceutical 1 95-98% -0.6649 1040 ['103771410', '405023478', '472422269', '476262831', '476269368'] HS-006;HS006;HS 006;RHCACD20MA